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ABSTRACT 
 
Background. Nonmalignant portal vein thrombosis is a significant event in the course of 
cirrhosis, known to affect the most severe patients. Its impact on liver disease progression 
or decompensation is not clear but it is known to decrease survival after liver 
transplantation. Some associated risk factors have been described but are not consensual 
or have not been validated to date. 
Aims. To determine i) risk factors for the development of nonmalignant portal vein 
thrombosis in the context of cirrhosis, and ii) the impact of the thrombotic event on liver 
disease progression, decompensation or death (secondary aim). 
Methods.  Two prospective observational longitudinal studies were conducted. 
THROMBOCIR, a multicenter study, undertaken between June 2000 and March 2006, on 
1243 Child-Pugh A and B patients, and FRTVPCir, a single-center study, undertaken 
between January 2014 and February 2017, on 108 patients, mostly Child-Pugh A (78%). 
Abdominal Doppler ultrasound study was performed in each of the studies every 3 or 6 
months. 
Results.  Global incidences of portal vein thrombosis of 9.5% and 10.2% were found in 
THROMBOCIR and FRTVPCir studies, respectively. Factors found to be related to the 
future development of portal vein thrombosis were medium or large-sized esophageal 
varices at baseline in both studies (hazard ratio [HR]=2.14; 95% confidence interval [CI]: 
1.27-3.60; P=0.004 and HR=5.67; 95% CI: 1.49-21.63; P=0.011 in THROMBOCIR and 
FRTVPCir studies, respectively), increased prothrombin time in the THROMBOCIR study 
(HR=0.82; 95% CI: 0.68-0.98; P=0.03), and the use of non-selective beta-blockers, but 
only in univariate analysis in THROMBOCIR (HR=1.67; 95% CI: 1.02-2.73; P=0.04); however 
in the FRTVPCir study, the use of non-selective beta-blockers was a related risk factor 
(HR=10.56; 95% CI: 1.35-82.73; P=0.025) independently of its effect over decreased heart 
rate or portal vein blood flow velocity. No relationship was found between decreased 
portal blood flow velocity and portal vein thrombosis in either study. Subanalysis of 
inflammatory markers in the FRTVPCir study revealed interleukin-6 above 5.5 pg/mL 
(HR=5.64; 95% CI: 1.21-26.33, P=0.028) and lymphopenia (HR=0.18; 95% CI: 0.04-0.80, 
P=0.023) at baseline as predictors for future portal vein thrombosis. Higher interleukin-6 
titers were related to more severe portal hypertension (presence of esophageal varices 
grade ≥ 2 and collaterals). In the largest study, portal vein thrombosis shared some of the 
same risk factors (esophageal varices size and increased prothrombin time) with but was 
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not related to liver disease progression, decompensation or death. 
Conclusions.  In compensated cirrhosis, portal vein thrombosis is a significant event 
occurring in approximately 1 in every 10 patients. Associated risk factors are those related 
to a more severe grade of portal hypertension (presence of and more advanced grades of 
esophageal varices), slightly advanced liver insufficiency (increased prothrombin time, 
only seen in the most powerful study), and inflamed patients (increased interleukin-6). 
Non-selective beta-blockers act over portal vein thrombosis development by mechanisms 
other than their direct effect over systemic or splanchnic circulation. Portal vein 
thrombosis does not impact liver disease progression or induce decompensation. 
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RESUMO 
 
Contexto.  A trombose da veia porta, na ausência de malignidade, é um evento 
significativo no curso da cirrose, afetando normalmente os doentes mais graves. Apesar 
de relacionada com uma diminuição da sobrevida após transplante, o impacto que a 
trombose da veia porta tem na progressão ou descompensação da doença hepática não é 
evidente. Alguns fatores de risco têm sido descritos. Contudo, além de não consensuais 
carecem, também, de validação.  
Objetivos.  Determinar i) fatores de risco associados ao desenvolvimento de trombose da 
veia porta não maligna no contexto de cirrose, e ii) o impacto do evento trombótico na 
progressão e descompensação da doença hepática, assim como na sobrevida dos doentes. 
Métodos.  Foram conduzidos dois estudos prospetivos longitudinais observacionais. O 
estudo THROMBOCIR, multicêntrico, conduzido entre Junho de 2000 e Março de 2006, 
incluiu um total de 1243 doentes com cirrose Child-Pugh A e B. O estudo FRTVPCir, 
unicêntrico, conduzido entre Janeiro de 2014 e Fevereiro de 2017, incluiu 108 doentes, a 
maioria com cirrose Child-Pugh A (78%). Ecografia abdominal com estudo Doppler foi 
realizada a cada 3 ou 6 meses. 
Resultados.   A incidência global de trombose da veia porta foi de 9.5% e de 10.2% no 
estudo THROMBOCIR e FRTVPCir, respetivamente. As varizes esofágicas de pelo menos 
grau 2 à inclusão relacionaram-se com o desenvolvimento futuro de trombose da veia 
porta em ambos os estudos (hazard ratio [HR]=2.14; 95% intervalo de confiança [IC]: 1.27-
3.60; P=0.004 e HR=5.67; 95% IC: 1.49-21.63; P=0.011 no estudo THROMBOCIR e FRTVPCir, 
respetivamente), o aumento do tempo de protrombina no estudo THROMBOCIR 
(HR=0.82; 95% IC: 0.68-0.98; P=0.03) e o uso de beta-bloqueadores não cardio-seletivos 
em análise univariada no estudo THROMBOCIR (HR=1.67; 95% IC: 1.02-2.73; P=0.04). No 
estudo FRTVPCir, a utilização de beta-bloqueadores não cardio-seletivos foi identificada 
como fator de risco para desenvolvimento da trombose da veia porta (HR=10.56; 95% IC: 
1.35-82.73; P=0.025) independentemente do seu efeito na diminuição da frequência 
cardíaca ou velocidade do fluxo a nível da veia porta. Nenhuma relação entre velocidade 
do fluxo da veia porta diminuída e o evento trombose foi identificada em qualquer dos 
estudos. A subanálise dos marcadores inflamatórios no estudo FRTVPCir mostrou que 
níveis de interleucina-6 superiores a 5.5 pg/mL (HR=5.64; 95% IC: 1.21-26.33, P=0.028) e a 
linfopenia presentes à inclusão eram preditores da ocorrência futura de trombose da veia 
porta. Níveis de interleucina-6 mais elevados foram encontrados nos doentes com 
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hipertensão portal mais pronunciada (presença de varizes esofágicas de pelo menos grau 2 
e de colaterais porto-sistémicas). No estudo maior, a trombose da veia porta partilhou 
alguns dos mesmos fatores de risco (presença de varizes esofágicas e tempo de 
protrombina aumentado), mas não esteve relacionada com a progressão ou 
descompensação da doença hepática assim como com incremento da mortalidade. 
Conclusões. Na cirrose compensada, a trombose da veia porta não maligna é um evento 
significativo e que ocorre em aproximadamente 1 em cada 10 doentes. Os fatores de risco 
que lhe estão associados são aqueles relacionados com maior expressão clínica de 
hipertensão portal (varizes esofágicas de pelo menos grau 2), marcadores de insuficiência 
hepática ligeiramente mais avançada (aumento do tempo de protrombina, apenas 
documentado no estudo com maior poder estatístico), e doentes mais inflamados (títulos 
elevados de interleucina-6). Os beta-bloqueadores não cardio-seletivos contribuem para o 
desenvolvimento de trombose da veia porta através de outros mecanismos que não pelo 
efeito direto sobre a circulação sistémica ou esplâncnica. A trombose da veia porta não 
tem impacto na progressão da doença hepática nem induz descompensação. 
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CHAPTER I  
INTRODUCTION 
 
1 .  THESIS MOTIVATION 
 
When I first started my residence in Internal Medicine back in 2005, at the Centro Hospitalar 
Universitário do Porto (CHUP), I never could have imagined where I would be or what I would be 
doing today. Since this tertiary health institution is one of the 3 centers in Portugal where liver 
transplantation (LT) is done, it seemed reasonable, as resident, to do an internship in Hepatology 
at an international reference center in Europe. After helpful advice from Prof. Helena Miranda, 
Paris would be my next stop. It was in 2008 that I was, for a period of 6 months, resident at the 
Liver Unit of Hôpital Beaujon – Clichy, France. By that time, I gained a particular appreciation for 
vascular liver diseases, probably influenced by Prof. Dominique Valla, who was responsible for the 
Liver Unit at the time. After that period, and back at CHUP, I ended my residency and started to 
work as an assistant, dedicating almost half of my time to the care of patients with liver diseases. 
In 2012 I was invited to go back to Paris, by that time as a hepatologist. In order to leave CHUP for 
Hôpital Beaujon, I was asked to start a PhD, and it seemed quite clear to me that it should be on 
vascular liver diseases, which would be one of the major pathologies I would come across on the 
ward I would be working on. Deciding on a subject and a specific area to start investigating was 
simple: Portal vein thrombosis (PVT) would be the main subject, due to its prevalence and 
eventual impact on cirrhosis, and the specific issue to be addressed would be the risk factors for 
its development, as they had not been clearly recognized, mainly due to the heterogeneity of the 
methodologies applied in the previously published papers. This would be the opportunity to study 
this particular issue in-depth and proceed to a critical examination while conducting an original 
work. Since the stay in Paris was only foreseen for one year, the research had to be undertaken in 
two steps, the first in Paris, with the THROMBOCIR (multicenter) study and the second one 
conducted in Porto, the FRTVPCir (single-center) study. Both of these prospective studies shared 
some common hypotheses and aims, even though particular designs were assessed.  
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2.  THESIS HYPOTHESES 
 
Hypothesis 1. Portal vein thrombosis is a significant event in patients with cirrhosis, with an 
increased incidence depending on the severity of the liver disease. Features related to portal 
hypertension markers and to the degree of liver failure are responsible for PVT development. 
 
Hypothesis 2. Blood stasis is one of the pillars of Virchow’s triad leading to thrombosis. A 
decreased portal blood flow velocity (PBFV) is a risk factor for PVT development in patients with 
cirrhosis.  
 
Hypothesis 3. Non-selective beta-blockers (NSBB) decrease portal hypertension via β1 and β2 
blockade. Their use in patients with cirrhosis is associated with future PVT development. 
 
Hypothesis 4. Factor V Leiden (FVL) and G20210A prothrombin (PTHR) gene mutations are well-
known risk factors for thrombosis. Their role in PVT genesis in patients with cirrhosis is not 
completely clear so far. Factor V Leiden and PTHR gene mutations are concurrent risk factors for 
PVT development in cirrhosis. 
 
Hypothesis 5. Inflammatory response and coagulation cascade activation has been recognized as 
inducing vascular thrombosis in different vascular territories, but no studies have been conducted 
so far with reference to splanchnic vessel bed. Increased inflammatory markers exist in patients 
with cirrhosis before PVT development.  
 
Hypothesis 6. Recent longitudinal data have changed the notion that PVT leads to liver 
decompensation and increased morbid-mortality out of the LT setting, but no prospective studies 
have been done so far. Portal vein thrombosis is not related to liver decompensation or 
progression. 
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3.  SPECIFIC AIMS 
 
Concerning hypotheses 1, 2 and 3, our aims were: 
- To search for risk factors, commonly seen on a daily clinical basis, which could be related 
to portal hypertension (size of esophageal varices, low platelet count, spleen size, ascites, 
hepatic encephalopathy [HE]), the degree of liver failure (increased prothrombin time 
[PT]/ international normalized ratio [INR] and bilirubin, low albumin, increased model for 
end-stage liver disease [MELD] score), PBFV or the use of NSBB (THROMBOCIR and 
FRTVPCir studies). 
 
Concerning hypothesis 4, our aims were: 
- To evaluate the prevalence of FVL and PTHR gene mutations in a large cohort of patients, 
to compare to the population in general and search for the competing risk for PVT 
development in patients with cirrhosis (THROMBOCIR study). 
 
Concerning hypothesis 5, our aims were:   
- To search for inflammatory markers (leukocytes, high-sensitive C reactive protein [Hs-
CRP], ferritin, tumor necrosis factor–alpha [TNF-α], interleukin [IL] - 6) that could be 
related to an increased risk for PVT development (FRTVPCir study). 
 
Concerning hypothesis 6, our aims (secondary aim) were: 
- To search for the impact of PVT on liver decompensation and progression, and mortality in 
a large cohort of prospectively followed patients (THROMBOCIR study). 
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4.  THESIS OUTLINE 
 
This thesis is divided into 7 chapters: 
 
Chapter 1: Establishes the main motivations, hypotheses and aims of the work. 
 
Chapter 2: Reviews the literature concerning the most important and significant works conducted 
so far in the field of portal vein thrombosis in patients with cirrhosis, bearing in mind that 
manuscripts published after our first published results and which refer our own data are not 
mentioned in this section but afterwards in the discussion, when applicable.  
 
Chapter 3: Broadly outlines the methodology applied in the two prospective studies conducted 
(THROMBOCIR and FRTVPCir). Detailed methodologies are described in the corresponding 
published articles. 
 
Chapter 4: Describes the results found in both studies in a “hypothesis-step” approach, referring 
to the published results (whenever applicable) presented as appendices, and in a detailed way to 
non-published results. Respective publishers authorized the reproduction of the published 
manuscripts. 
 
Chapter 5: Provides a general discussion of the main results. 
 
Chapter 6: Resumes the major findings and outcomes of the studies. 
 
Chapter 7: Describes the clinical implications of our findings and addresses future fields of 
research. 
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CHAPTER II  
L ITERATURE REVIEW 
 
Cirrhosis, the ultimate stage of liver fibrosis progression, histologically characterized by 
conversion of normal liver architecture into hepatocyte-containing nodules surrounded by bands 
of fibrous tissue of various breadth (1), has a heterogeneous distribution worldwide, reflecting 
different etiologies and diagnostic assessment tools (2). However, the real prevalence of cirrhosis 
is difficult to ascertain, being estimated to range, in necropsy studies, between 4.5% and 9.5% of 
the general population (3). After a clinically silent period, cirrhosis complications arise and are 
reflected by loss of hepatocellular function, portal hypertension complications (ascites, 
hypertensive gastrointestinal bleeding [GB], HE), hepatocellular carcinoma (HCC) or extrahepatic 
complications (renal impairment, hepatopulmonary syndrome, infection, acute-on-chronic liver 
failure, etc.) (4-6). Patients with compensated liver disease have median survival rates of more 
than 12 years, with survival rapidly decreasing with decompensated disease (4). Cirrhosis is the 11th 
most common cause of death, being responsible for 1.16 million death/year and still rising (2). 
Portal vein thrombosis refers to the presence / development of a clot within the portal vein tract, 
along the portal vein trunk and/or one or both of its branches, which may, or may not completely 
occlude the vessel (7). In cirrhosis, it may course asymptomatically and be found in the context of 
a routine abdominal exam (for example in the setting of HCC screening) or with symptoms, 
namely abdominal pain, depending on the extension of the clot within the superior mesenteric 
vein harboring a poor prognosis, or those related to liver disease decompensation (7). Importantly, 
PVT must be differentiated from malignant vascular invasion, which in patients with cirrhosis is 
almost always related to HCC, being a clinically distinct entity harboring a different treatment 
and prognosis. Doppler-ultrasound (DUS) findings may aid in differential diagnosis, 
demonstrating an absent flow in the portal vein or one or two of its branches by color Doppler 
study, but contrast-enhanced ultrasound (CEUS) allows for a final diagnosis in more than 97% of 
the patients (8). Magnetic resonance (MRI) or contrast-tomography scan (CT-scan) confirms not 
only the diagnosis but also determines the extension of the clot within the splanchnic vessel bed 
(7). Once PVT is diagnosed, anticoagulation is usually the treatment to be offered, in order to i) 
avoid extension and ii) promote PVT resolution. Yet, not all the patients with PVT and cirrhosis are 
candidates for anticoagulation, and there is probably a subgroup of patients to which this 
treatment should be offered immediately (after adequate screening and respective treatment of 
esophageal varices), i.e. those who are candidates for or on the waiting list for LT, while other 
patients should be considered individually and according to local policies and experience 
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(Appendix 1)(7, 9, 10). 
 
 
1 .  THE EPIDEMIOLOGY OF PVT 
Older reports on PVT incidences and prevalences show some discrepant results reflecting 
different geographic regions, methodologies and study designs (most of them retrospective or 
cross-sectional in nature) as well as different technics / diagnostic procedures. Furthermore, the 
indistinct use of the terms incidence and prevalence in literature interfere with epidemiological 
data interpretation. In England, in 1954, in 111 patients with cirrhosis, PVT was documented 
intraoperatively in 11% of them (11). Even though no stratification was made, all patients 
presented with decompensated liver disease by the time of PVT diagnosis. In Hong-Kong, a 
necropsy study gathering 126 cirrhotic patients documented mural thrombi involving portal vein in 
25.4% of the cases (12). By contrast, in Japan, a very low prevalence of 0.6% was reported in 708 
patients followed for a 10-year period in a mixed population of Child A to C patients (most of 
them Child C) (13). The diagnosis was based on angiographic studies (either transhepatic or 
superior mesenteric arterial portography). Other ancient reports, also using invasive diagnostic 
tools such as surgical technics or angiography, are in line with the heterogeneity of the 
aforementioned results, with prevalence ranging from 5.2% to 21% (14-18). Even so, the highest 
prevalences of PVT are those reported among patients undergoing LT, reflecting an underlying 
more severe liver disease. Nonami et al reported a 15.7% PVT prevalence by the time of LT in 
patients with end-stage cirrhosis (19). Gayowski et al, in a cohort of 88 American veterans, found 
prevalence even higher of 26% by the time of LT (20). All of them were Child-Pugh C. After 
excluding patients with HCC, another study documented a prevalence of PVT at LT of 17.5% (21). In 
a cohort of patients listed for LT and longitudinally followed, a 1-year incidence of PVT of 7.4% 
was reported, with the diagnosis made by DUS (22). Other studies also include mostly patients 
with advanced liver disease, even if not on a LT waiting list. Amitrano et al reported PVT 
prevalence of 11.2% in 701 patients admitted to the hospital (90% were Child-Pugh B and C), most 
of them due to an acute episode of liver disease decompensation (23). Villa et al, in a group of 
Child-Pugh B7-C10 cirrhotic patients found PVT up to 16,6% per year (24).  A recent prospective 
assigned study enrolling a mixture of 81 Child-Pugh A to C cirrhotic patients, showed a 1-year 
incidence of PVT of 15% (25). 
As such, PVT in cirrhosis is found, today, to be a non-negligible event, with discrepant reported 
incidences and prevalences, but clearly more recognized in patients with more severe liver disease, 
such as those candidates for LT or admitted at the onset of an acute episode of decompensation, 
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while clear estimates of the incidence or prevalence of PVT in less severe liver disease patients is 
not known. 
 
 
2.  CLASSIFICATION SYSTEMS 
Several PVT classifications have been proposed since 1991 after the work of Stieber et al (26). This 
was purely anatomical and the first classification involving the whole portal venous system. 
Others succeed, but most of them refer only to anatomical considerations, as the location and 
extension of PVT (19, 27, 28). The most known and used PVT classification is the one proposed by 
Yerdel et al, which has implications in LT decisions and techniques to be applied (29). Bauer et al 
also proposed a pure anatomic classification that is useful for therapeutic monitoring purposes 
(30). It was only after the recent Baveno report that parameters other than anatomy were 
considered, such as the time setting of the thrombotic event (recent versus chronic) or the 
etiology of the underlying liver disease (10). Yet, functional aspects and outcomes were not 
included. The main issue is to have a PVT classification that allows not only to stratify according 
to location and extension, time setting and underlying etiology, but also one that enables to 
consider the subset of patients that will most benefit from anticoagulation treatment. The 
proposal of a new anatomic-functional classification system gathering all these aspects has been 
recently undertaken, which now requires external validation (Appendix 2) (31). 
 
 
3.  NATURAL HISTORY AND CLINICAL IMPACT OF PVT 
 
3.1 .  PVT outcome without anticoagulation 
Six decades ago, Laws et al, advanced the already existing notion that PVT would start as a 
thrombus partially occluding the lumen that could i) evolve, extending to complete thrombosis; 
ii) lead to cavernomatous transformation with the formation of numerous collateral veins 
running alongside the portal vein or; iii) spontaneously revert with complete recanalization of the 
vessel lumen (32). 
Still, the natural history of PVT was not known until recently, when two recent retrospective 
longitudinal studies showed that PVT, once established and not treated, had a remarkable 
potential of reversal. Luca et al, in a cohort of 42 patients with partial extrahepatic non-malignant 
PVT, observed a spontaneous decrease in the thrombi volume in 45% of the patients, while in 21% 
it remained unchanged. Only 17% of the patients evolved to complete PVT, and none developed 
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portal cavernoma (33). In another population of 150 virus-related cirrhotic patients, 42 were 
diagnosed with PVT, 31 of which with partial PVT. Overall, PVT improved in 48% of the patients, 
remained unchanged in 45% and worsened in only 7% of the cases, with no portal cavernoma 
development (34). Recurrence of PVT after previous spontaneous resolution occurred in 9 
patients, showing that PVT may have a dynamic character (34). Also, John et al, in a prospective 
study gathering 290 patients listed for LT, found that 30% of the patients with PVT at inclusion 
and 35% that developed PVT while on the waiting list, recanalized at least partially without any 
treatment (35). Yet, others haven’t found these optimistic results. Francoz et al found no 
spontaneous resolution of PVT without anticoagulation in their cohort (22), however only 10 
patients didn’t received anticoagulation, and even if all PVT were partial, the follow-up period (5.8 
months) was short, meaning that more time may be needed for recanalization (22). Also, after 6 
months of follow-up, Zocco et al found 2 patients with total and 3 patients with partial PVT. Six 
months after the diagnosis, none of them regressed and one complete thrombosis evolved to 
portal cavernoma (25). Once again, not only is the number of events scarce, but follow-up was 
too short to draw any conclusions concerning the potential reversal of PVT with time. 
 
3 .2.  Impact of  PVT on progression and decompensation of l iver  disease 
The notion that PVT may lead to progression and decompensation of liver disease is well-known, 
being the result of data published by the time of the thrombotic event (cross-sectional) and not 
by prospectively conducted studies. In 1954, Hunt et al, after the description of 7 patients with PVT 
suggested that its occurrence could be related to some sort of liver decompensation (variceal 
hemorrhage, HE, ascites, deterioration of the clinical condition), even if no other symptoms other 
than those associated to portal hypertension could occur (11). In a cohort of 701 patients admitted 
to the hospital due to an episode of liver decompensation, with advanced liver disease, PVT was 
often diagnosed at the same time, in 79 (11.2%) of them (23). And by the time of LT, PVT was also 
more commonly found in patients with concomitant decompensated liver disease (patients with 
chronic HE, ascites and GB) (19). This means that PVT may be more frequent in patients with 
advanced or decompensated liver disease, but it is not possible to extrapolate if it is the cause of 
decompensation, solely based on these cross-sectional studies. However, reasonable 
pathophysiological explanations may corroborate the aforementioned results. A work conducted 
by Wanless et al, involving 61 explanted cirrhotic livers found, in 36% of them, some degree of 
intimal fibrosis within the portal vein (involving intra-hepatic segments), which is in a higher range 
when compared to other works with lower prevalence of (extra-hepatic) PVT, using methods 
other than the examination of the whole liver (36). The occlusion of portal venules lead to 
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adjacent tissue collapse, creating areas of microinfarcts and “parenchymal extinction” which, in 
turn, will be replaced by fibrous septa (36, 37). This aggravation in intrahepatic block leads to an 
increase in portal hypertension that could precipitate, at least in theory, a liver decompensation 
event. When a branch of the portal vein is selectively ligated, there is a decrease in homolateral 
hepatic volume, proportional to the degree of ligation with a compensatory hypertrophy of the 
contralateral lobule (38, 39). The degree of necrosis is also related to more severe degrees of 
occlusion (38). While transforming growth factor beta (an antiproliferative factor, inducer of 
apoptosis) overexpression in the embolized lobe leads to hepatocyte apoptosis and subsequent 
atrophy, in the non-embolized lobe, transforming growth factor alpha (a mitogenic polypeptide, 
which activates signaling for cell proliferation) overexpression leads to hepatocyte proliferation 
and related lobe hypertrophy (40). Extrapolation of occlusion of a portal vein branch to portal 
vein trunk must be seen with extreme caution.  
Still, and in opposition to the aforementioned, older data, mainly based on cross-sectional 
studies, PVT is usually accidently found in an asymptomatic patient (7, 23, 34). Recent longitudinal 
studies show that PVT is not a cause for liver decompensation. Luca et al found that progression 
of PVT did not lead to more episodes of liver decompensation, death and specific portal 
hypertension complications, and that the severity of liver failure ad initium would be the 
precipitating factor related to liver decompensation in the future and not PVT itself (33). Also, 
John et al noted no increased GB episodes in patients with PVT (35). 
Nevertheless, the liver has a particular dual afferent vessel system, leading to a 
hyperarterialization after a decrease in portal vein blood flow. This capacity of the hepatic artery 
to buffer changes in portal blood flow has been well documented (41, 42). If this mechanism is of 
importance and explains why in recent longitudinal studies no decompensation seems to arise 
after PVT, is still a field open to investigation. 
In short, cross-sectional studies, documenting PVT by the time of a liver decompensation episode 
suggest the possibility of a cause-and-effect relationship. However, recent longitudinal studies 
suggest that PVT and liver decompensation are not directly related, but probably share common 
precipitating risk factors. 
 
3 .3.  Impact of  PVT on survival  
The impact of PVT on survival may be different when considering patients transplanted or not 
transplanted with PVT. 
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3.3.1 .  Impact of  PVT on survival  without LT 
Maruyama et al, found similar cumulative 10-year survival for patients with and without PVT (34). 
John et al, found similar results in patients while on the waiting list for LT (35). Recently, in a case-
control study, survival was not affected by PVT irrespective of the degree of occlusion (43). The 
analysis of a large LT recipient population (22291 patients) showed that those who developed PVT 
while on the waiting list didn’t die more (44). Curiously, in an analysis made using the United 
Nation for Organ Sharing (UNOS) database involving 66506 patients listed for LT, patients with 
PVT presented a lower mortality than those without (45). There is no data concerning whether 
anticoagulation was given or not, which may bias the result. The heterogeneity of the different 
studies concerning not only the inclusion of patients with and without HCC but also the length of 
the follow-up may give rise to different results. A systematic review of 13 different manuscripts 
clearly showed this heterogeneity but also that PVT could negatively impact the short-term (at 5-
day, 6-week or 1-year), and the long-term survival (3-year follow-up) (46). However, this 
conclusion is drawn from abstracts and not published papers (47) so no final conclusions can be 
drawn regarding the negative impact of developing PVT on survival in cirrhotic patients out of the 
LT setting. 
 
3 .3.2.  Impact of  PVT on survival  with LT 
Almost all the studies reporting survival after LT are retrospective in character (9). Gayowski et al., 
found no impact on patient survival, but PVT correlated with worse graft survival (20). Others saw 
no poor outcome after LT. Dumortier et al. found similar 1-year post-LT survival rates for those 
with (83.7%) and without PVT (86.7%), but most patients transplanted with PVT (89%) had 
partial occlusion of the vein (48). Other groups found similar results (49-51). John et al., in a 
prospectively conducted study, showed no impact on short-term (6 months) survival post LT (35). 
Yet, others report contrasting conclusions, with an increased PVT-related mortality after LT (22, 
29, 44, 52). Two recent studies, both involving several hundreds of liver transplanted patients 
collected from the Organ Procurement and Transplantation Network (OPTN) database, but in 
different periods of time, clearly show a worse patient and graft early (90-days) (53) and long (up 
to 8 years of follow-up) post-LT survival (54). Yet, HCC was identified as being one of the risk 
factors for PVT development while on the waiting list in both papers and no mention has been 
done to if this negative impact on survival had some relationship to cancer relapse after LT or not. 
These conflicting results have been addressed in two recent meta-analyses. The first, showed that 
occlusive PVT before LT had a negative impact in the 1-year post-LT survival (55). The second, 
gathering more published data, showed that 30-day and 1-year post-LT survival was worse in 
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patients that had PVT previous to LT (56). Also, they documented that within PVT patients, 30-day 
survival was significantly worse according to higher degrees of portal vein occlusion and this 
relation, even if maintained at 1-year after LT did not met statistical meaning (56). The negative 
impact of PVT on LT and survival may be related to the extension and degree of the clot (29, 56), a 
more complex and prolonged time of surgery (29, 49, 54), higher transfusion requirements (49, 
57), and longer intensive care unit and hospital stays (58). 
In short, the current notion is that PVT does not impact survival outside of the LT setting and also 
that higher degrees of occlusion bear dismal prognosis after LT.  
 
 
4.  KNOWN RISK FACTORS FOR PORTAL VEIN THROMBOSIS IN CIRRHOSIS 
 
4.1 .  Virchow’s tr iad 
Thrombosis, occurring at any site or blood vessel bed, is a consequence of not one but many risk 
factors that, acting together, induce clot formation under special circumstances. Virchow’s triad 
is helpful in explaining this theory while addressing this multifactorial concept based on three 
fundamental pillars: a hypercoagulable state, blood stasis and endothelial damage (59). These 
fundaments may also be applied to PVT in order to systematize the already known risk factors and 
to aid in further investigation fields. 
 
4.1 .1 .  Hypercoagulable state 
   4 .1 .1 .1 .  Hemostasis  in  advanced l iver  disease 
To understand the role of hemostasis in the genesis of PVT in the particular context of cirrhosis, 
some notions must be cleared concerning the current knowledge on hemostasis in advanced liver 
disease. Patients with cirrhosis are often found to have disturbed routine laboratory tests such as 
PT/ INR, bleeding time and platelets. In contrast to what was previously believed these tests were 
suggested to be of no use to predict the risk of bleeding in cirrhosis (60). 
Hemostasis is a sequential process and depends on the interaction of platelets, wall vessels and 
clot factors. Primary hemostasis refers to the process in which the loose platelet plug is formed 
on the injured vascular endothelium and secondary hemostasis refers to the cascade that allows 
stabilization the clot with the conversion of fibrinogen into fibrin (61). 
Platelets.  Thrombocytopenia (<150.000/µL) is a common (up to ¾ of the patients) and an early 
finding in patients with cirrhosis being, most of the time, moderate (62, 63). When severe, 
although rare (platelets <40.000/µL are expected to occur in about 1% of the patients), a work up 
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must be done in order to exclude other concurrent causes, such as infection, active alcohol 
consumption, immunological disorders or others (62, 64). In cirrhosis, a low platelet count may be 
mainly explained by: i) portal hypertension and related hypersplenism, which leads to splenic 
pooling and the sequestration of platelets from the circulation (65-67); ii) low thrombopoetin 
levels related to platelet underproduction which also seems to be dependent on the severity of 
liver disease (67, 68); and iii) the presence of antiplatelet antibodies (69, 70), even though their 
presence in cirrhotic patients are not always consistent with thrombocytopenia (71). In spite of 
these quantitative platelet defects that could favor a bleeding tendency, compensatory 
mechanisms exist that may counteract this occurrence. Von Willebrand Factor (VWF) is a 
multimeric protein extremely important in primary hemostasis. When binding to the exposed 
subendothelium collagen fibers of an injured vessel wall, VWF contributes to platelet adhesion 
and clot formation. In cirrhosis, VWF is elevated and rises in relation to the severity of liver disease 
(72-74), and may even predict decompensation episodes and mortality (74). The higher titers of 
VWF in this context may be explained by i) endothelial damage; ii) endotoxemia; iii) 
overexpression in the liver; iv) higher endothelial total surface (explained by the presence of 
extensive collaterals); v) higher endogenous vasoconstrictor levels; and vi) a reduced VWF 
clearance (72-74). Also, a disintegrin and metalloproteinase with a thrombospondin type 1 motif, 
member 13 (ADAMTS-13), which is a cleaving protease of VWF, was found to be decreased in a 
manner that is inversely related to liver disease severity, possibly contributing to higher circulating 
VWF levels (75, 76). Overall, the elevated circulating titers of VWF may compensate qualitative 
and quantitative platelet defects (73). Platelets are also important for thrombin generation and 
capable of doing so since their number does not usually fall below 60.000/µL (77). In short, severe 
thrombocytopenia in cirrhosis is rare (and apparently not more frequent than in chronic liver 
diseases without cirrhosis) (62) and mechanisms exist that seem to compensate the quantitative 
and qualitative platelet defect, such as higher VWF levels and a preserved capacity of thrombin 
generation, for an adequate adhesiveness and aggregation. 
Coagulation.  The liver is responsible for the production of several pro- and anticoagulant 
factors. Accordingly, it is expected that a more severe liver disease relate to a parallel reduction of 
the aforementioned factors, which would explain the prolonged conventional global coagulation 
tests such as PT, INR or the activated partial thromboplastin time (78). However these tests are 
not suitable to assess the coagulation balance in cirrhosis, since they do not express the whole 
amount of thrombin generated in the absence of protein C activators (79). As previously stated, 
thrombin generation in cirrhosis is preserved provided there is a sufficient platelet number. Also, 
it is now known that thrombin is generated in at least the same amount in the plasma of patients 
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with cirrhosis when compared to healthy subjects: this occurs according to in vitro conditions 
resembling those in vivo, using methods reflecting the action of both anticoagulants and 
procoagulants, for example with the presence of thrombomodulin or Protac® (an extract of snake 
venom that also activates Protein C in vitro) (80, 81). 
A few years ago a remarkable difference between the variation of pro- and anticoagulant factors 
was found in the course of the liver disease, favoring the tendency of higher levels of pro- versus 
anticoagulants, the so called “imbalance of coagulation”. A recognized reduction of the 
anticoagulant levels of Protein C, S and antithrombin was not accompanied in the same way and 
proportion by some procoagulant factors, namely factor VIII (a very important driver for thrombin 
generation), which is actually raised (80, 82). The ratio factor VIII: Protein C in cirrhotic patients 
increases according to the severity of liver disease being around 3 in Child-Pugh A and reaching 
values of 5.6 in the more severe Child-Pugh C patients (80, 81). While low levels of Protein C are 
explained by a deficit of synthesis, the elevated levels of factor VIII are due to decreased clearance 
mediated by VWF and low-density lipoprotein receptor-related protein (83). 
F ibr inolysis .  Once coagulation is activated and a clot forms, the way to prevent its extension 
and an increased risk of thrombosis is to degrade fibrin. This is achieved with the conversion of 
plasminogen to plasmin by profibrinolytic drivers, which are opposed by antiactivators avoiding 
hyperfibrinolysis that would otherwise potentiate bleeding, with most of the involved proteins 
and enzymes being produced by the liver (84). In cirrhosis, both hyperfibrinolysis and 
hypofibrinolysis have been described. Laboratory abnormalities commonly present in cirrhosis 
express a probably restored balance between pro- and antifibrinolytic factors, since findings of 
increased tissue plasminogen activator and plasmin activity, and decreased α-2 plasmin inhibitor, 
plasminogen and thrombin-activatable fibrinolysis inhibitor have been described (85-88).  
 
   4 .1 .1 .2 .  Altered hemostasis  and portal  vein thrombosis  
As previously mentioned, PVT is known to occur with more frequency in patients with more severe 
liver disease. The most severe liver patients are also those who will have the more profound 
hemostasis alterations, making it reasonable to try to establish a connection between the two. 
Platelet count has been found to be inversely correlated to the risk of PVT occurrence in patients 
on the waiting list for LT, which might be explained by the impact of portal hypertension, which 
could surpass any protective role of thrombocytopenia (22), as confirmed in two other studies as a 
baseline finding (25, 89), thrombocytopenia being independently associated with the 
development of PVT in one of them in multivariate analysis (89). Thrombocytopenia has also been 
found to be correlated to PVT by other groups (90). Yet, these results must be approached with 
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caution, since laboratory data that is measured at the time of the event may not be representative 
of a causative relationship/risk factor, but may be an actual consequence of the event, i.e., the 
low platelet count may be due to platelet consumption occurring associated to thrombosis (91). 
Others did not find thrombocytopenia to be a risk factor for PVT development (34). Patients with 
cirrhosis are now known to be at risk for venous thromboembolism (92, 93), recently confirmed in 
a robust meta-analysis (94), and acquired coagulopathy does not protect against the thrombotic 
event (94, 95). While the use of venous thromboembolism prophylaxis is still low and neglected, 
there is consensus of the benefits of putting these patients, while hospitalized, under mechanical 
or medical prophylactic measures (9, 94, 95). Tripodi et al hypothesized that the coagulation 
imbalance expressed by the increased factor VIII and decreased protein C could explain the higher 
risk of venous thromboembolism (80). When looking specifically at what happens at the level of 
the portal vein axis, Kalambokis et al found no relation between increased factor VIII level, but an 
independent association of the ratio factor VIII-to-protein C with PVT development, reflecting the 
role of the coagulation imbalance in promoting PVT (96). These results were not replicated by 
others, which found no association between procoagulant imbalance and PVT (97). But 
prospectively conducted studies are lacking to study the role of coagulation imbalance as a risk 
factor in PVT development. Chen et al found no important differences between groups with and 
without PVT when considering the ratios of pro- versus anticoagulant factors, but the population 
studied was small and the data was collected after PVT occurrence, not before (98). Tang et al 
showed progressively decreased levels of anticoagulant factors (Protein C, Protein S and 
antithrombin) in relation to liver disease severity with constant levels of factor VIII, as well as a 
lower Protac®-induced coagulation inhibition percentage, all these findings related to a greater 
procoagulant imbalance (97). However, no relationship between these results and PVT was found, 
even when stratified for the severity of the liver disease. Once again, the study included patients 
already with PVT, making it difficult to extrapolate a causal relationship (97). Zocco et al found 
that in spite of being a constant in all patients with cirrhosis, when considering those with higher 
MELD scores (at least 13 points), Protein C, Protein S and antithrombin levels were significantly 
lower and correlated with PVT occurrence (25). In short, prospective studies are lacking when 
trying to establish a link between coagulation imbalance and PVT development in cirrhosis. 
Decreased Protein C (24, 25), Protein S (25) or antithrombin levels (25) and increased D-dimer 
levels (25) have been associated with an increased risk for subsequent PVT development. The 
other available studies, either of retrospective or cross-sectional character, have analyzed risk 
factors determined at the time of the diagnosis of the thrombotic event (97-102). 
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   4 .1 .1 .3.  Genetic  factors  
Studies performed before the 2000’s, enrolled a small number of patients and mixed those with 
and without cirrhosis, which led to conflicting results, notably in what concerns to FVL mutation 
and PVT occurrence in cirrhotic patients (103, 104). After that period, more studies were published 
enrolling only patients with cirrhosis and analyzing mainly the role of FVL, PTHR and 
Methylenetetrahydrofolate reductase C677T (MTHFR) mutations. Amitrano et al found a 
thrombophilic genotype in 69,5% of the 23 patients with cirrhosis and diagnosis of PVT, with all of 
the aforementioned mutations being of statistical significance (105). These results were almost 
all supported by Erkan et al, which found FVL mutation to be more frequent (hazard ratio 
[HR]=11.45; 95% confidence interval [CI]: 1.98-66.24; P<0.01) in patients with cirrhosis and PVT 
compared to those without, finding the same result for PTHR mutation (HR=11.45; 95% CI: 1.98-
66.24; P<0.01), but not for MTHFR mutation (106). But once again a very small group of 17 patients 
was analyzed, with large CI found (106). With a bigger group of 701 cirrhotic patients, 79 of them 
with PVT, Amitrano et al found a five times higher risk for the development of PVT in carriers of 
the PTHR mutation, but not with FVL or MTHFR mutations (23). The mutation of the G20210A 
prothrombin gene consisting in a substitution of a GàA at nucleotide position 20210 leads to 
higher plasma prothrombin levels. The same group also documented the role of a heterozygote 
state for PTHR mutation and elevated levels of plasma factor II, as well as the ratio factor 
II:Protein C, reflecting the prothrombotic/antithrombotic balance favoring PVT development 
(107). Later on, Mangia et al prospectively enrolled 43 patients with cirrhosis and PVT achieving 
different conclusions: i) a lower prevalence of a thrombophilic genotype than previously reported 
and stated above, of 27,9%; ii) no relationship between the presence of any of FVL, PTHR or 
MTHFR mutations and PVT occurrence (108). Not even two recently published meta-analyses laid 
this uncertainty to rest (109, 110). They used different methodologies, considering the analysis of 
the two major mutations: FVL and PTHR. The first one, gathered patients with and without 
cirrhosis, small case series and did not exclude HCC for study selection, concluding that the 
presence of FVL mutation does not confer a significantly increased risk for PVT in cirrhosis 
(estimated risk of 1,99%), as opposed to cirrhotic patients carriers of PTHR mutation, with an 
estimated attributable risk for PVT of 9,37% (109). The second one excluded the previously 
mentioned possible bias from the analysis. The found prevalence of FVL mutation was 
significantly higher in patients with cirrhosis and PVT than in those without the event (HR=2.55; 
95% CI: 1.29-5.07; P=0.007), while the prevalence of PTHR mutation was not different between 
both groups (HR=2.93; 95% CI: 0.94-9.07; P=0.06) (110). In this last case a subgroup analysis was 
conducted, separating 1 Asian and 4 European studies, with no differences seen among the 
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European studies between both groups (PVT versus no PVT) (110). When considering only the role 
of MTHFR mutation, it is known that in a homozygous state it leads to high homocysteine levels. 
Some considerations about its role in PVT in cirrhosis have previously been mentioned. Another 
meta-analysis found that the presence of MTHFR mutation in homozygosity increases the risk of 
PVT in cirrhotic patients (111). Regardless of the uncertainty, current guidelines recommend the 
screening of underlying inherited thrombophilic conditions (7, 10). 
Janus Kinase-2 (JAK2) gene is responsible for the control of the production of blood cells from 
hematopoietic stem cells; its mutation, described in 2005, has been linked to myeloproliferative 
disorders (MPD) (112). Myeloproliferative disorders are the cause of PVT in approximately 25% of 
the patients, and JAK2 mutation has been found to be present in 16% to 34% of non-cirrhotic 
patients with PVT (113, 114). However, in patients with cirrhosis few studies have been conducted 
so far, but similarly as in non-cirrhotic patients, there also seems to be a relationship between 
JAK2 gene mutation and PVT. Saugel et al recently reported in a small case-control study a 
tendency (although with no statistical meaning) for those patients with cirrhosis harboring the 
mutation to develop PVT, when compared to those who did not (115). Despite the fact that these 
results still need to be urgently reproduced on a larger scale, the latest Baveno VI consensus 
suggests the addition of JAK2 mutation analysis in the systematic screening of a cirrhotic patient 
developing PVT, similarly as for non-cirrhotic patients (10). 
More recently, an association between the calreticulin (CALR) gene mutation and MPD was found; 
CALR and JAK2 mutations are mutually exclusive (116). Splanchnic vein thrombosis was found to 
be associated with the CALR mutation in non-cirrhotic patients in a Spanish cohort, but in a 
frequency far lower than JAK2 mutation and, when considering only PVT, the mutation was only 
described in 2 out of 140 patients (1,4%) (117). This low prevalence (0,7% considering PVT and 
Budd-Chiari syndrome all together) was also reported in a case-control study from the EN-Vie 
study cohort (118). Still, when considering only non-cirrhotic patients with JAK-2 V617F negative 
MPD, CALR mutations may be present in up to 31% of patients with PVT (116), but corresponding 
data in patients with cirrhosis are still lacking and no studies have been conducted so far 
regarding CALR mutation and PVT relationship in cirrhosis. 
 
   4 .1 .1 .4.  Antiphospholipid antibodies 
Antibodies reacting against negatively-charged phospholipids were described 30 years ago to be 
associated with two patients with hepatitis B virus induced cirrhosis by Violi et al (119). Later on, 
the same group, in a cohort of 20 cirrhotic patients, found a significant positivity for 
anticardiolipin antibodies in 9 of them (120). A significant association between antiphospholipid 
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antibodies, both lupus anticoagulant and anticardiolipin antibodies, and splanchnic thrombosis in 
patients with cirrhosis (cohort of 73 patients with cirrhosis mixed etiologies with 9 splanchnic 
thrombotic events, 8 of which PVT) was found a little later, also by the same group (121). A case-
control (10 PVT cirrhotic patients matched with 20 cirrhotic patients without PVT) study reached 
the same results with positivity for anticardiolipin antibodies being significantly related to PVT 
(122). Notwithstanding the presence of antiphospholipid antibodies in patients with chronic liver 
diseases and its association to histological severity (123) and autoimmune etiology (124) (which 
probably represents an immunological epiphenomenon due to an hyper stimulation of the 
immune system) (125), their definitive role in the genesis of PVT is yet to be established. Amitrano 
et al found no relationship between the presence of antiphospholipid antibodies (anticardiolipin 
and beta-2-glycoprotein-I antibodies) and PVT in patients with cirrhosis in a study matching 50 
patients with and without liver cirrhosis and with and without PVT (126). A meta-analysis recently 
reinforced the notion that there doesn’t seem to be a causal effect of antiphospholipid presence 
on PVT occurrence (127). However there are only limited studies addressing this particular issue, 
with non-standardized methodologies and few patients. Importantly, there is no mention in any 
study concerning reevaluation of antiphospholipid antibodies titer 12 weeks after their initial 
measurement, not allowing any particular conclusion regarding its role in PVT genesis and related 
antiphospholipid syndrome to be drawn.  
 
4.1 .2 .  Blood stasis  
In 1856, Virchow stated that “phenomena due to the interruption of the blood-stream” was one of 
the factors leading to thrombosis illustrating, in this way, one of the pillars of his triad (59). In the 
natural history of chronic liver diseases, hepatic stellate cell activation, dysfunction of the liver 
sinusoidal endothelial cells, microvascular thrombosis and progressive architectural distortion, 
promote an increase in the intrahepatic vascular resistance leading to portal hypertension (128). 
Also, collateral vessel formation, and arterial and splanchnic vasodilation are other typical 
findings resulting, after the application of the hydraulic derivation of Ohm’s Law (Pressure = Flow 
x Resistance) in an increase in portal hypertension (129).  
In patients with cirrhosis, PBFV has long ago been recognized to be slower than in normal 
individuals (18) and lowers in proportion to the severity of the disease (expressed by Child-Pugh 
classification) (130) and higher degrees of fibrosis (131). A PBFV of 15cm/s has been set as the best 
cut-off value for the detection of portal hypertension by DUS study, with sensitivity and specificity 
of 88% and 96%, respectively (130). Also, PBFV has been related to a worse prognosis with a 
shortened survival when <10cm/s (132). 
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   4 .1 .2 .1 .  Decreased portal  vein blood flow velocity  and PVT 
It was long ago, back in 1954, that Hunt et al stated that “stagnation of blood in the main portal 
vein is probably the only constant etiological factor of real importance” for PVT development in 
cirrhosis (11). However many years passed until this issue came to light once again, with Amitrano 
et al hypothesizing portal blood flow stasis as the most important risk factor favoring PVT (133). 
Only more recently, Zocco et al found a significant relationship between a decreased PBFV (< 
15cm/s) and PVT development (HR=44.9; 95% CI: 5.3-382.7; P<0.001) in a prospectively conducted 
study enrolling 73 patients followed for 1 year (25). Beyond the hemodynamic implication on PVT, 
she proposed that stagnation of portal blood flow could lead to higher levels of thrombin in 
portal circulation due to a deficient washout (25). This theory has not yet been confirmed. The low 
number of thrombotic events (twelve) and the resulting large CI means these results should be 
viewed with caution. Corroborating this finding, Abdel-Razik et al, achieved a similar result, with 
PBFV < 15cm/s at baseline predicting a significantly higher occurrence of PVT, with a mean basal 
value of 11.6±4.3cm/s for those who developed PVT versus 17.9±4.5cm/s (P<0.001) for those who 
did not (89). In a case-control study in which 50 PVT cirrhotic patients were matched with 50 
cirrhotic patients without PVT, similar results were found, with a 6 times higher risk for 
developing PVT for each cm/s decrease in portal blood flow velocity below the cut-off of 15 cm/s 
(43). Chen et al, found no differences in PBFV between groups in a study involving 162 patients, 40 
of which with documented PVT; however, this was cross-sectional study in design, not allowing a 
rigorous assessment of risk factors for PVT (90). A longitudinal retrospective study found same 
results (34). In a randomized controlled trial focusing on enoxaparin treatment in cirrhotic 
patients, a lower mean PBFV was not found to be a risk factor for PVT (24).  Even though a 
decreased PBFV is considered to be a risk factor for PVT development and is an attractive 
hypothesis to explain PVT, there is a need for prospective studies with greater patient number and 
with well-standardized measurements of PBFV to be conducted. 
Non-selective beta-blockers are routinely used on patients with cirrhosis in the context of primary 
or secondary prophylaxis of variceal bleeding (10), due to their effect on reducing portal 
hypertension via β1 (lowers cardiac index) and β2 receptor blockade (induces splanchnic 
vasoconstriction) (134). Non-selective beta-blocker use also lowers bleeding-associated mortality 
(135). However, despite these positive effects of NSBB, the reduction of PBFV and related effect on 
PVT genesis by inducing blood stasis has been hypothesized (136). Preliminary results of a small 
cohort of 56 patients with cirrhosis only presented in an abstract form, found NSBB to be a risk 
factor for PVT development (137). The role of NSBB on PVT genesis has not yet been confirmed.  
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   4 .1 .2 .2.  Other markers of  portal  hypertension 
As previously stated, the severity of the intrahepatic blockade is related to increased portal 
hypertension which, in turn, may lead to a deceleration of the PBFV, increasing local blood stasis 
and precipitating PVT development. It is reasonable, therefore, to search for other markers of 
portal hypertension and try to relate them with PVT. 
Systemic collaterals.  Portosystemic collaterals are vessel structures that are formed in order 
to bypass an occlusion or an anatomic distortion, from a high to a low-pressure vascular bed 
(138).  They may be classified in 4 groups, one where the protector epithelium joins the absorption 
epithelium leading to esophageal, gastric and rectal varices; a second group with the 
recanalization of the falciform ligament through the umbilical vein; a third group with vascular 
collaterals formed in the contact zones of abdominal organs with retroperitoneal tissue or 
adjacent to the abdominal wall; and a fourth group with a portosystemic shunt through the renal 
vein (139). Studies addressing the role of systemic collaterals on future PVT occurrence are lacking. 
Maruyama et al, in a longitudinal retrospective study enrolling only virus-related cirrhotic 
patients, found baseline flow volume in the largest collateral vessel (left gastric vein, short gastric 
vein and splenorenal shunt were evaluated) as an independent risk factor for PVT development 
(34). This increased risk could be related to a “stolen effect” causing deviation of blood from the 
portal vein trunk to collateral vessels leading to local stasis. However, the authors, found no 
difference in PBFV in patients developing, or not, PVT. Also, they state that the presence of 
collaterals would lead to a deviation of active thrombin from the portal vein trunk (34), 
contradicting Zocco’s previous theory (25). Gastroesophageal varices are collateral vessels/ 
portosystemic shunts. An acute upper hypertensive bleeding episode has been named as the 
major sign of PVT, and has been found in up to 82.4% of patients experiencing PVT (18). The 
concomitant presence of PVT in the acute variceal bleeding setting has long been related to a 
more severe bleeding episode and increased rebleeding rates in a population of cirrhotic patients 
that underwent portal decompressive surgery as treatment for upper hypertensive hemorrhage 
(17). Nonami et al found a statistically significant association between previous GB and PVT 
occurrence by the time of LT; however being a study with a retrospective character, no causal 
effect could be established (19). Francoz et al found that previous variceal bleeding in a cohort of 
cirrhotic patients listed for LT was a risk factor for PVT in multivariate analysis (22). In a cross-
sectional study also enrolling only cirrhotic patients awaiting LT, only a past history of variceal 
bleeding increased 2.5 times the risk of PVT (140). However Hernandez-Conde et al did not find a 
previous upper GB episode to be a risk factor for subsequent PVT occurrence, in their longitudinal 
retrospective study (141), nor did Villa et al in their randomized trial (24). So, gastroesophageal 
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variceal bleeding may be a form of clinical presentation of PVT, but if there is a cause-effect 
relationship must still be established in future prospective studies. Variceal bleeding can, 
otherwise, reflect a more severe state of portal hypertension that could be expressed by the size 
of esophageal varices. However, no relationship between the degree of esophageal varices and 
PVT has been found by the majority of published papers to date (22, 24, 25, 89). Importantly, it is 
also necessary to establish if the presence of bigger gastroesophageal varices or their bleeding, 
mirroring more severe portal hypertension also reflects diminished PBFV favoring, in this way, 
PVT.   
Hypersplenism and its  consequences.  Banti was the first to relate the presence of reduced 
peripheral blood cells to enlarged spleens, but it was Chauffard who first used the term 
“hypersplenism” in 1907 (65). The spleen has a particular anatomic relationship with the liver 
through the portal vein system, so that portal hypertension (irrespectively of the etiology) is 
considered one of the multiple causes leading to splenomegaly and consequent hypersplenism 
with thrombocytopenia and other cytopenias (65, 142). The role of portal hypertension in spleen 
enlargement is also reinforced in studies showing a decrease in spleen size and related 
hypersplenism in patients after undergoing LT (66). Nevertheless, and even though after LT an 
almost complete normalization of splanchnic circulatory changes is seen, spleen size does not 
completely normalize in most of the patients, meaning that the  “hyperplasia” component does 
not resolve after LT (143). However, the increase in spleen size in the context of the intrahepatic 
blockade, such as the one occurring in cirrhosis, has not been systematically found to be directly 
correlated to an increase in portal pressure in most of the older studies (144-146), but to a related 
increase in splenic arterial inflow (145) and pulp hyperplasia (146, 147). So, splenomegaly must also 
be attributed to mechanisms other than an increased portal hypertension alone, which means 
that the term “congestive splenomegaly” is an over simplification to justify spleen enlargement in 
cirrhotic patients. However, studies enrolling more patients and with the current methodologies 
to measure portal pressure (notably the hepatic venous pressure gradient) are lacking in order to 
definitively clarify this issue. If the cirrhotic liver and related portal hypertension may aid in 
justifying splenomegaly, the opposite is also true. In cirrhotic patients, there is evidence of local 
splenic production of endothelin-1, and it has also been documented that higher endothelin-1 
levels exist in splanchnic when compared with systemic circulation (148). This endothelial factor is 
now known to be involved in the pathogenesis of the intrahepatic blockade, inducing local 
vasoconstriction and fibrogenesis (147) and also to increase portal pressure gradient values (149). 
Thus, the spleen is still a piece of the portal hypertension hemodynamics puzzle which has to be 
completely resolved, but evidence exists that the cirrhotic liver may account for splenomegaly 
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and that splenomegaly may contribute to liver disease progression, both justifying an increased 
portal hypertension. 
If the spleen is related to local hemodynamic disturbance, splenomegaly and its consequences 
may be linked to an increased risk of PVT development. An increased spleen size (34) and splenic 
thickness (89) was documented more frequently in patients developing PVT by some authors. A 
related hypersplenism translated by thrombocytopenia was also found to be an independent risk 
factor for PVT (22, 89). However, others did not confirm this independent effect of low platelet 
count on PVT development (24, 25). 
Ascites.  With the increase in portal hypertension secondary to liver fibrosis progression, and 
collateral formation, splanchnic and systemic vasodilatation occurs leading to the activation of 
the renin-angiotensin-aldosterone system and sympathetic nervous system ultimately promoting 
renal sodium and water retention supporting ascites formation (150). In the context of cirrhosis 
and portal hypertension, ascites also relates directly to the severity of the hepatic venous pressure 
gradient (151). A decreased PBFV was found in patients with ascites (152), which is ultimately 
linked to local blood stasis, possibly favoring PVT. However, even though ascites has been found 
to be a risk factor for PVT development by some authors (34, 35, 53), this has not been 
consistently found among studies (24, 140), mirroring different methodological approaches not 
only in the design of the study and patients enrolled, but also in the grading/ classification of 
ascites.  
 
4 .1 .3.  Endothelial  damage 
The endothelium is a major organ comprising the entire circulatory system with a vast number of 
functions currently recognized (153). Fluid filtration, adjustment of the vascular tone, hemostasis 
and endocrine functions sum up some of its purposes (153, 154). These functions may be disturbed 
by local or systemic inflammation or shear stress leading to endothelium dysfunction and the 
creation of a prothrombotic and antifibrinolytic microenvironment favoring local thrombosis (153, 
155). Wanless et al has already proposed that intimal inflammation within the smallest veins and 
sinusoids of the liver could induce thrombosis (36). Even though endothelial damage and 
dysfunction is recognized as one of the pillars of Virchow’s triad, no studies have been conducted 
so far studying this in relation to PVT. However, it is possible to theorize about the relationship 
between endothelial dysfunction and PVT. 
Inflammation and infection.  The luminal surface of the endothelial cell is covered by a sort 
of sheath, the endothelial glycocalyx layer, which comprises many macromolecules with many 
functions, one of them being the regulation and adhesion of platelets and leucocytes, important 
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in the inflammatory response, as well as in the cytokine-mediated enzymatic degradation of the 
layer in this context (156). Sepsis has long ago been recognized as a model for endothelial 
glycocalyx layer change in conformation with shedding induced by reactive oxygen species, TNF-α, 
heparanase, and bacterial endotoxins among others (157). This inflammatory environment is of 
major importance in explaining multiorgan failure with vasodilatation, increased vascular 
permeability and activation of the coagulation cascade (157). There are some common points that 
maybe be shared by the endothelial dysfunction in sepsis and cirrhosis in order to try to establish 
a model between inflammation and thrombosis.  
Von Willebrand Factor.  The multifunctional acute-phase glycoprotein VWF is synthesized by 
the endothelial cell, being secreted by the constitutive or the inducible pathway, this last one 
being activated by inflammatory stimuli via TNF-α, IL-6 and IL-8 (157, 158). The ultra large 
multimers of VWF formed in this context are highly thrombogenic, while inducing platelet 
activation and aggregation, being “dismantled” by ADAMTS-13 in order to maintain homeostasis 
in normal conditions (158, 159). Von Willebrand factor also has a role in promoting inflammatory 
cascade by contributing to leukocyte adhesion (160) and complement cascade activation (161). 
Increased levels of ultra large multimers of VWF and decreased levels of ADAMTS-13 have been 
found in association with disseminated intravascular coagulation, severe sepsis and complicated 
malarial infection, allowing a link to be established between inflammation/ infection and 
coagulation activation (159). Increased VWF levels have been consistently found to be related to 
venous thrombosis (162) and have already also been found to be an independent risk factor for 
PVT development only by a group of researchers (96). As VWF levels are upregulated in cirrhosis in 
proportion to liver disease severity (72-74), they can play a role in PVT development which may be 
related to endothelial dysfunction (163).   
Endotoxin/ L ipopolysaccharide. The intestinal epithelial barrier is characterized by normal 
functioning tight and adherens junctions that become disrupted in the context of cirrhosis, portal 
hypertension, hepatotoxins as alcohol and related acetaldehyde, and local expression of pro- and 
anti-inflammatory interleukins (as IL-6, TNF-α, interferon gamma) (164). Lipopolysaccharide (LPS), 
a major component of the gram-negative bacterial wall, is an endotoxin that, together with other 
microbial products such as peptidoglycan, lipopetides and bacterial DNA, may translocate from 
the disrupted intestinal lumen to the mesenteric lymph nodes and other extraintestinal sites 
(165). The proximity of the gut and the liver establishes a close relationship with direct drainage to 
the splanchnic vessel bed comprising portal vein. Endotoxemia has long been recognized to be 
present in patients with liver disease in higher levels than in healthy individuals and its titer rises 
in proportion to the severity of the liver disease according to Child-Pugh’s class (166). The 
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relationship between endotoxemia and thrombosis in other vessel beds other than portal vein has 
long been documented. In rabbit animal models, the injection of endotoxin of Escherichia coli 
immediately induced microvascular thrombosis (167). Lipopolysaccharide was also found to 
increment thrombus extension in arterial and venous vessel beds after its administration in a 
murine animal model and after the induction of initial thrombus by local ferric chloride injection 
(168). In humans, microvascular thrombosis and disseminated intravascular coagulation (DIC) has 
been associated to fatal cases of meningococcal septicemia induced by the liberation of 
endotoxin (169). Other cases of DIC have been well documented in severe sepsis induced by gram-
negative bacteria (170). Endotoxin may promote thrombosis while inducing the expression of VWF 
(171) and toll-like receptor 4 (TLR4) (172), which is a primary signaling receptor for LPS. Also, LPS 
may induce the production of TNF-α and IL-6, both leading to tissue factor expression by 
endothelial cells and subsequently to DIC and eventually thrombosis (170). Downregulation of 
thrombomodulin (TM) is another way by which LPS may induce thrombosis. Thrombomodulin is a 
transmembrane glycoprotein mainly synthesized by vascular endothelial cells that serves as a 
receptor for thrombin, reducing its procoagulant activity and therefore having anticoagulant 
properties (173). In the absence of TM, thrombin activates fibrinogen to generate fibrin inducing 
clot formation (174). In patients with sepsis and DIC, TM is downregulated facilitating and 
perpetuating coagulation and inflammatory cascade (174). The inhibitory effect of TM was found 
to be lost in a murine model in which LPS, after being administered to mice, induced activation of 
coagulation confirmed by the measurement of thrombin-antithrombin complex, with an increase 
in endogenous thrombin potential (175). Starr et al also documented an increase in fibrin 
formation, no increase in activated protein C and a profound and sustained downregulation of TM 
expression after LPS administration to mice, mainly seen in the older but not the younger animals 
(176). This downregulation of TM during endotoxemia was also described in a group of young 
septic patients with severe meningococcemia (177) and in another mouse model with LPS 
administration in which fibrin deposition was verified in the organs, particularly in the endothelia 
of the liver (178). Overexpression of tissue factor and downregulation of TM have been found to be 
LPS-dose dependent (179). If LPS is recognized to induce microvascular thrombosis/ DIC while 
inducing overexpression of VWF, TLR4, tissue factor, cytokines liberation and downregulation of 
TM, and if LPS levels are raised in cirrhosis in relation to the degree of portal hypertension and 
bacterial translocation, it is reasonable to consider that LPS may play a role in PVT genesis. Violi et 
al has addressed this issue proposing that a hypercoagulable state induced by overexpression of 
tissue factor and VWF secondary to endotoxemia, as a consequence of endothelial dysfunction, 
would be determinant to splanchnic and systemic vein thrombosis in cirrhosis (180). However, no 
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specific prospective study has ever been made addressing this issue. 
Local  inflammation/ infection/ injury. The relationship between local inflammation and 
thrombosis was established more than a century ago (181). Portal vein thrombosis associated to 
local infection or in contiguous structures to the portal system characterizes pylephlebitis (182). In 
a recent retrospective study enrolling 95 patients from Mayo Clinic, pancreatitis, diverticulitis and 
peritonitis were the leading conditions associated to pylephlebitis, with bacteremia found in 44% 
of the patients (183). However, whether cirrhosis confers a different added risk for pylephlebitis 
development is yet to be determined, since no studies have ever addressed this issue. 
Spontaneous bacterial peritonitis (SBP) refers to primary infection of the peritoneal fluid with 
cultural positivity in approximately 40% of the cases, in which Escherichia coli is the most 
commonly isolated gram-negative bacteria (5). A Spanish retrospective longitudinal study 
enrolling cirrhotic patients listed for LT found, in univariate analysis, SBP as being more frequent 
among those who developed PVT (141). However, a prospective study conducted by Villa et al 
found no relationship between previous episodes of SBP and PVT occurrence (24).  
Splenectomy, colectomy and other intra-abdominal surgeries as well as abdominal trauma and 
portocaval shunt procedures are some of the local risk factors that have been identified as 
promoters of PVT while inducing direct endothelial damage, but are not specific to cirrhosis (184). 
 
4.2.  Beyond Virchow’s tr iad 
Considerations must be undertaken if a specific etiology for cirrhosis is implicated in a more 
prothrombotic environment, eventually related to an increased inflammatory milieu and so an 
increased risk for PVT development. Consensus on this subject does not exist. Amitrano et al 
found a more common hepatitis specific viral etiology among 72% of patients with PVT (23). 
Maruyama et al in a retrospective longitudinal study enrolling 150 patients with virus-related 
cirrhosis noted a prevalence of 28% of PVT, which is higher than other series with mixed etiologies 
of cirrhosis (34). Autoimmune hepatitis (21), cryptogenic cirrhosis (21, 53), nonalcoholic 
steatohepatitis (53, 54, 185) have been found to be related to PVT development. However, others 
did not find any relationship between the etiology of underlying liver disease and PVT 
development. (20, 25, 89, 140) These discrepant results may result from bias of selection, different 
methodological approaches for inclusion and regional discrepancies concerning etiologies of 
cirrhosis. However, if some etiology is found to be associated to PVT development, the most 
probable cause is the related proinflammatory environment and eventual link to endothelial 
damage, once again bringing up one of the pillars of Virchow’s triad. 
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CHAPTER II I  
MATERIALS AND METHODS 
 
 
1 .  THROMBOCIR STUDY (186)  –  A PPENDIX 3  
This study was conducted in Paris, France. It gathered 1243 Child A and B patients deviating from a 
multicenter cohort (43 liver referral centers in France and Belgium) of 1278 patients prospectively 
followed (Protocol CHC 2000), and whose primary purpose was to address the best periodicity (3- 
versus 6-month) for HCC screening, after exclusion of 35 patients with PVT at inclusion (187). This 
study was registered at clinicaltrials.gov website 
(http://clinicaltrials.gov/ct2/show/NCT00190385). Patients were enrolled between June 2000 and 
March 2006. At each visit clinical and biological parameters were recorded. All patients 
underwent DUS allowing registration of PBFV and occlusion of the portal vein trunk or its 
branches when present. A more exhaustive and detailed methodology description can be found in 
the published article (186). 
 
 
2 .  FRTVPCIR STUDY (188)  –  A PPENDIX 4  
This study was conducted in Porto, Portugal. This was a prospective, single-center study (CHUP) in 
which patients with cirrhosis were enrolled between January 2014 and February 2017. Patients with 
cirrhosis irrespective of the etiology and degree of liver failure were included, provided they had 
not had a previous splanchnic or extra splanchnic vein thrombosis, HCC or were under 
anticoagulation or anti-aggregation treatment. At each visit, a complete follow-up protocol was 
filled with demographic data, health status characterization and clinical examination. Blood 
sample collection and abdominal DUS were also performed. When PVT was suspected by the 
Doppler study, confirmation by a CT-scan on the same day was required. Detailed methodology 
concerning patient selection and study design, follow-up and data collection, abdominal DUS and 
portal vein diagnosis and statistical analysis is reported in the published article (188). 
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2.1 .  Specif ic  considerations for subanalysis  of  inflammatory markers and PVT 
development (unpublished results)  
 
2 .1 .1 .  Patient selection and study design 
Patients with active infection or hospitalization in the previous 3 months and who were under 
anti-TNF-α therapy were excluded from final analyses along with all the exclusion criteria 
reported elsewhere (188). 
 
2 .1 .2 .  Blood collection and processing  
Blood was drawn without stasis from a peripheral vein, after proper local disinfection with 
chlorhexidine 2% solution, in tubes containing sodium citrate 3.2%, ethylenediaminetetraacetic 
acid - EDTA or clot activator and immediately transported to the laboratory. Blood was 
centrifuged at 2500G for 15 minutes according to local laboratory protocol. Standard analyses 
were immediately performed at the central biochemical laboratory of CHUP. Serum and plasma 
were stored in aliquots of 200µL and 500µL in 1,5mL tubes and frozen and stored at -80ºC. Total 
blood was also stored at -20ºC. 
Enzyme-linked immunosorbent assays (ELISA) were performed using Triturus ELISA instrument®. 
For specific analysis of TNF-α and IL-6, Citomed® commercialized reagents were used: Human 
TNF-α Quantikine® ELISA Immunoassay kit (Ref.aDTA00C) and Human IL-6 Quantikine® ELISA 
Immunoassay kit (Ref.aD6050). Tumor necrosis factor alpha and IL-6 determinations were done 
according to specific protocols following the manufacturer’s instructions with calibrators and 
samples processed in duplicate. Lower cutoff values of 15.6 pg/mL and 3.13 pg/mL were used 
considering a population of healthy donors with TNF-α and IL-6 levels inferior to the calibrator of 
the lower concentration. 
 
2 .1 .3.  Statist ical  analysis  
Summary statistics, namely, percentages, means or medians (normal distribution was assessed 
using the Kolmogorov‐Smirnov test) and respective standard deviations or interquartile range 
were computed. Comparisons between continuous variables and the occurrence of PVT were 
made using independent samples t test or Mann‐Whitney U test for skewed distributions. Cause‐
specific hazards were modeled using the Cox proportional hazards model, with the cause‐specific 
HR as the measure of the association between covariates and outcome. Log‐linear relationships 
and proportional hazards assumptions were checked. Multivariate models included variables 
significantly associated with the outcome in univariate analyses at a level of 5% as well as 
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variables previously reported to be associated with an increased risk of PVT in patients with 
cirrhosis. A step‐wise selection procedure was used. Ninety‐five percent CI’s were computed. 
Time‐dependent covariates were used to assess the predictive value of time‐dependent 
measurements of PBFV on the hazard of the development of PVT. As the Kolmogorov‐Smirnov 
test for normality (together with graphic observation of the distribution) indicated that IL-6 didn’t 
follow a normal distribution, the median values were presented and used for comparisons. The 
comparison of the median IL-6 values according to patient characteristics was estimated using 
the non-parametric Kruskal-Wallis test. 
Statistical analyses were performed using Stata version 11.2 for Windows (Stata Corp LP, College 
Station, TX, USA). 
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CHAPTER IV 
RESULTS 
 
1 .  THESIS STUDIES OUTLINE 
The results presented in this thesis are derived from the two main prospective studies – 
THROMBOCIR, appendix 3 (186) and FRTVPCir, appendix 4 (188). The first, the largest longitudinal 
study published to date, gathering information collected in 43 liver referral centers in France and 
Belgium and, the second, comprising data collected in a single LT center in Portugal – CHUP. 
 
HYPOTHESIS AIMS RESULTS/  STUDY 
1. Features related to portal 
hypertension markers and to 
the degree of liver failure are at 
the genesis of PVT 
development. 
To determine PVT risk factors 
related to portal hypertension 
(size of esophageal varices, low 
platelet count, spleen size, 
ascites, HE) and the degree of 
liver failure (increased PT/ INR 
and bilirubin, low albumin, 
increased MELD). 
THROMBOCIR and FRTVPCir 
Studies. 
2. Decreased PBFV is a risk 
factor for PVT development in 
patients with cirrhosis. 
To determine a possible cause-
effect relationship between 
decreased PBFV and PVT 
development. 
THROMBOCIR and FRTVPCir 
Studies. 
3. The use of NSBB in patients 
with cirrhosis is related to 
future PVT development. 
To determine the relationship 
between NSBB use and PVT 
development. 
To find possible ways NSBB 
induce PVT. 
THROMBOCIR and FRTVPCir 
Studies. 
 
FRTVPCir study 
4. Factor V Leiden and PTHR 
gene mutations are concurrent 
risk factors for PVT 
development in cirrhosis. 
To determine FVL and PTHR 
gene mutations and to settle 
competing risk for PVT 
development. 
THROMBOCIR study 
5. Increased inflammatory 
markers exist in patients with 
cirrhosis before PVT 
development. 
To determine inflammatory 
markers (leukocytes, Hs-CRP, 
ferritin, TNF-α, IL-6) and 
related risk for PVT 
development. 
FRTVPCir study – unpublished 
results 
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HYPOTHESIS AIMS RESULTS/  STUDY 
6. PVT is not related to liver 
decompensation. 
(Secondary aim of the study) 
To determine the impact of 
PVT on morbidity 
(decompensation and 
progression of liver disease) 
and mortality. 
THROMBOCIR study 
 
Table 1 .  Thesis studies outline gathering general information concerning hypotheses, respective aims and 
the study conducted to achieve the correspondent results. 
 
The THROMBOCIR and FRTVPCir studies are presented in Appendices 3 (186) and 4 (188), 
respectively. 
 
Appendix 3 
Causes and consequences of portal  vein thrombosis  in  1 ,243 patients with 
cirrhosis:  results  of  a  longitudinal  study. 
Nery F, Chevret S, Condat B, de Raucourt E, Boudaoud L, Rautou PLE, Plessier A, Roulot D, 
Chaffaut C, Bourcier V, Trinchet JC, Valla DC, Groupe d’Etude et de Traitment du Carcinome 
Hépatocellulaire. Hepatology. 2015 Feb; 61(2):660-7 
doi: 10.1002/hep.27546. Epub 2015 Jan 5. 
 
 
Appendix 4 
Nonselective beta-blockers and r isk of  portal  vein thrombosis  in  patients with 
cirrhosis:  results  of  a  prospective longitudinal  study. 
Nery F, Correia S, Macedo C, Gandara J, Lopes V, Valadares D, Ferreira S, Oliveira J, Gomes MT, 
Lucas R, Rautou PE, Miranda HP, Valla D. Aliment Pharmacol Ther. 2019 Jan 
Doi: 10.1111/apt.15137. Epub ahead of print.   
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2.  HYPOTHESES 1 ,  2  AND 3 
 
HYPOTHESIS AIMS RESULTS/  STUDY 
1. Features related to portal 
hypertension markers and to 
the degree of liver failure are at 
the genesis of PVT 
development. 
To determine PVT risk factors 
related to portal hypertension 
(size of esophageal varices, low 
platelet count, spleen size, 
ascites, HE, etc.) and the 
degree of liver failure 
(increased PT/ INR and 
bilirubin, low albumin, 
increased MELD, etc.). 
THROMBOCIR and FRTVPCir 
Studies. 
2. Decreased PBFV is a risk 
factor for PVT development in 
patients with cirrhosis. 
To determine a possible cause-
effect relationship between 
decreased PBFV and PVT 
development. 
THROMBOCIR and FRTVPCir 
Studies. 
3. The use of NSBB in patients 
with cirrhosis is related to 
future PVT development. 
To determine the relationship 
between NSBB use and PVT 
development. 
To find possible ways NSBB 
induce PVT. 
THROMBOCIR and FRTVPCir 
Studies. 
 
FRTVPCir study 
 
Table 2.  General information regarding hypotheses 1 to 3, respective aims and correspondent studies. 
 
Both cohorts mainly enrolled cirrhotic patients with a more stable liver disease. The 
THROMBOCIR study, involving 1243 patients, gathered 863 Child-Pugh A and 380 Child-Pugh B 
patients, with 118 patients (9.5%) developing PVT; while the FRTVPCir study, with 108 patients 
enrolled, 84, 19 and 5 Child-Pugh A, B and C patients, respectively, with 11 of them (10.2%) being 
diagnosed with PVT. Follow-up time was longer in the THROMBOCIR than in the FRTVPCir study 
(mean follow-up 47 months versus 19.4 months). 
 
Only medium or large-sized esophageal varices (HR=2.14; 95% CI: 1.27-3.60, P=0.004 and 
HR=5.67; 95% CI: 1.49-21.63, P=0.011 in the THROMBOCIR and FRTVPCir studies, respectively), as a 
variable related to a more severe degree of portal hypertension, was identified as a risk factor for 
PVT development in both studies (Tables 3 and 4, respectively). A more severe liver disease 
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documented with increased prothrombin time in the THROMBOCIR study was also one of the 
variables linked to PVT development (Table 3). 
Neither a decrease in PBFV with time in the THROMBOCIR study (Table 3) nor a lower PBFV at 
baseline in the FRTVPCir study (HR=1.04; 95% CI: 0.92-1.17, P=0.897) were associated to future 
PVT occurrence. 
 
 
THROMBOCIR STUDY 
Variable 
Univariate analysis Multivariate analysis 
HR 95% CI P HR 95% CI P 
Etiology of cirrhosis       
               HCV +/- alcohol 0.72 0.49-1.04 0.08    
               Alcohol 1.50 1.05-2.16 0.028    
Serum bilirubin (µmol/L) 1.16 1.06-1.27 0.001    
ALT (N<40 IU/L) 0.77 0.61-0.98 0.036    
Prothrombin time (%) 0.76 0.68-0.86 <0.0001 0.82 0.68-0.98 0.03 
Medium or large 
esophageal varices 
2.15 1.43-3.23 0.0002 2.14 1.27-3.60 0.004 
De novo ascites* 1.81 1.14-2.89 0.01    
Decreasing portal vein 
blood flow velocity* 
0.98 0.95-1.01 0.19    
Non-selective beta-
blocker* 
1.67 1.02-2.73 0.04    
 
Table 3.  THROMBOCIR main and significant risk factors in univariate and multivariate analysis; HCV, 
hepatitis C virus; ALT, alanine aminotransferase; *Predictive factors evaluated as time-dependent variables. 
(Adapted from Supplemental Tables 1, 2 and 3 from Nery F. et al, Hepatology 2015 [186]).  
 
 
Despite the fact NSBB were related to PVT development in univariate but not in multivariate 
analysis (Table 3) in the THROMBOCIR study, they played a role as a risk factor for future PVT 
occurrence in FRTVPCir (Table 4), independently of their effect on lowering heart rate or on 
decreasing PBFV. 
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FRTVPCir  STUDY 
Variable HR 95% CI P 
Esophageal varices 
(Medium/ Large vs Null/ small) 
   
                  Crude 5.67 1.49-21.63 0.011 
                  Adjusted for NSBB  2.45 0.55-10.89 0.238 
NSBB (yes vs no)    
                  Crude 10.56 1.35-82.73 0.025 
                  Adjusted for PBFV 12.47 1.58-98.43 0.017 
                  Adjusted for heart rate 13.66 1.51-123.85 0.020 
                  Adjusted for EV 6.15 0.63-59.96 0.118 
 
Table 4.  FRTVPCir multivariate Cox proportional models of predictive factors for portal vein thrombosis 
development, adjusted for potential confounders. NSBB, Non-selective beta-blocker; PBFV, Portal blood 
flow velocity (cm/s); EV, Esophageal varices (Adapted from Table 2 from Nery F. et al, Aliment Pharmacol 
Therap 2019 [188]). 
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3.  HYPOTHESIS 4 
 
HYPOTHESIS AIMS RESULTS/  STUDY 
4. Factor V Leiden and PTHR 
gene mutations are concurrent 
risk factors for PVT 
development in cirrhosis. 
To determine FVL and PTHR 
gene mutations and to settle 
competing risk for PVT 
development. 
THROMBOCIR study 
 
Table 5.  General information concerning hypothesis 4, respective aims and correspondent study. 
 
Factor V Leiden and PTHR gene mutations were searched for in the 3 most represented centers 
out of the 43 involved in the THROMBOCIR study: Beaujon, Jean Verdier and Avicenne Hospitals in 
302 patients out of a total of 428 enrolled in the 3 centers. After excluding Child C patients, 283 
patients were analyzed and FVL mutation was present in 5% of the patients (13 patients in 
heterozygosity and in 1 patient in homozygosity) and PTHR gene mutation in heterozygosity in 8 
(3%) of them. No relationship was found between the presence of either of these mutations and 
PVT development (HR=1.84; 95% CI: 0.68-4.98, P=0.23). 
 
 
  
CHAPTER IV - RESULTS 
	   43 
4.  HYPOTHESIS 5  
 
HYPOTHESIS AIMS RESULTS/  STUDY 
5. Increased inflammatory 
markers exist in patients 
with cirrhosis before PVT 
development. 
To determine inflammatory 
markers (leukocytes, Hs-
CRP, ferritin, TNF-α, IL-6) 
and related risk for PVT 
development. 
FRTVPCir study – 
unpublished results 
 
Table 6.  General information concerning hypothesis 5, respective aims and correspondent study. 
 
A panel of inflammatory markers usually used in the daily clinical routine setting (leucocytes, 
neutrophils, lymphocytes, Hs-CRP and ferritin) together with TNF-α and IL-6 were determined. For 
specific analysis of potential inflammatory markers as risk factors for PVT development, 107 
patients were considered from the FRTVPCir study. One patient out of 108 that was under anti-
TNF-α therapy (etanercept) for psoriasis was excluded from the final analysis. This specific patient 
did not developed PVT in the course of the follow-up. Portal vein thrombosis occurred in 11 out of 
107 patients (10.3%). 
Baseline clinical, laboratory and DUS findings are expressed in Table 7. No major differences exist 
when comparing the original cohort of patients. Tumor necrosis factor alpha levels were below 
the lowest limit of detection in all patients tested. Lower lymphocyte count and increased IL-6 at 
baseline were related to future PVT development (Table 8). As IL-6 did not follow a normal 
distribution, median values were taken into consideration, with a clear association to PVT 
development above 5.5 pg/mL (HR=5.64; 95% CI: 1.21-26.33, P=0.028). To determine the effect of 
IL-6 and lymphocytes on PVT development, adjustment to variables for potential confounders 
was performed (Table 9). The association between increased IL-6 values and PVT remained 
significant even after adjusting for all the considered variables at the same time (HR=8.79; 95% 
CI: 1.42-54.44). Low lymphocyte count at baseline was also a marker of future PVT occurrence 
(HR=0.18; 95% CI: 0.04-0.80, P=0.023). On average, lymphocytes decreased in both groups (PVT 
versus no PVT development) with time. The variation before the occurrence of the thrombotic 
event (an average decrease of 0.043 ± 0.364 x 109/L) was more pronounced (0.132 ± 0.163 x 109/L) 
than that which occurred in patients who did not develop PVT at the end of follow-up (0.033 ± 
0.394 x 109/L), even if with no statistical significance (P = 0.413). 
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 Without PVT (N=96) With PVT (N=11)  
Age (years) 54.1± 11.0 57.8 ± 8.5 
Male gender 69 (71.9%) 6 (54.5%) 
Aetiology of cirrhosis 
            Alcoholic 
                   Virala 
                   Alcoholic + Virala 
                   Metabolicb 
                   Autoimmune 
                   Cryptogenic 
 
43 (44.8%) 
14 (14.6%) 
11 (11.5%) 
12 (12.5%) 
12 (12.5%) 
4 (4.2%) 
 
4 (36.4%) 
1 (9.1%) 
3 (27.3%) 
0 (0.0%) 
3 (27.3%) 
0 (0.0%) 
Current alcohol use 7 (7.3%) 2 (18.2%) 
Current NSBB use 47 (49.0%) 10 (90.9%) 
Ascites 19 (19.8%) 4 (36.4%) 
Esophageal varices 
(grade≥2) 
28 (289.2%) 8 (72.7%) 
Child-Pugh A/ B/ C 74 (77.1%)/ 17 (17.7%)/ 5 (5.2%) 9 (81.8%)/ 2 (18.2%)/ 0 (0%) 
MELD ≥ 13 19 (19.8%) 2 (18.2%) 
Albumin (g/dL) 4.2 ± 0.6 3.9 ± 0.6 
TB (mg/dL) 1.5 ± 1.4 1.5 ± 0.6 
AST (U/L) 44.2 ± 31.7 44.2 ± 19.8 
ALT (U/L) 38.1 ± 31.6 29.5 ± 15.8 
INR 1.25 ± 0.24 1.26 ± 0.19 
Platelets (109/L) 109.3 ± 57.4 84.4 ± 37.7 
Portosystemic collaterals 21 (21.9%) 3 (27.3%) 
PBFV (cm/s) 20.4 ± 5.0 20.6 ± 6.1 
Spleen size (cm) 15.1 ± 3.4 16.1 ± 3.3 
Leucocytes (109/L) 5.2 ± 2.1 4.3 ± 2.1 
Neutrophils (109/L) 3.2 ± 1.3 2.7 ± 1.8 
Lymphocytes (109/L) 1.4 ± 0.7 0.95 ± 0.4 
Hs-CRP (mg/L) 5.4 ± 8.9  8.7 ± 10.7 
Ferritin (ng/mL) 290 ± 379 237 ± 302 
TNF-α (pg/mL) * * 
IL-6 (pg/mL) 
[Median (P25-P75)] 
4.8 (1.6-9.9) 7.6 (5.8-19.3) 
 
Table 7.  Clinical, abdominal Doppler ultrasound and laboratory findings, including considered 
inflammatory markers (shaded rows) at baseline in patients with cirrhosis who did or did not eventually 
develop portal vein thrombosis (PVT). Data are expressed as mean ± SD and categorical variables as 
frequencies (%). aHepatitis B virus and/ or hepatitis C virus; b Wilson’s disease or hemochromatosis or non-
alcoholic steatohepatitis or alpha-1 antitrypsin deficit; c NSBB, Non-selective beta-blockers; MELD, model 
for end-stage liver disease; TB, total bilirubin; AST, aspartate aminotransferase; ALT, alanine 
aminotransferase; INR, international normalized ratio; PBFV, portal blood flow velocity; Hs-CRP, high-
sensitive C-reactive protein; TNF-α, tumor necrosis factor alpha; IL-6, Interleukin-6; *All subjects with TNF-α 
levels below the lower limit of detection. 
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The risk of PVT development, when considering low lymphocyte count was, therefore, already 
present at baseline. Portal vein thrombosis developed more often in patients with lymphocyte 
count less than the median value of 1.2 x 109/L (Figure 1). Patients with lymphocyte count less 
than 1.2 x 109/L presented an almost 6 times higher risk of PVT (P = 0.041). 
 
 
 HR 95% CI  P 
Leucocytes (109/L) 0.74 0.50-1.09 0.127 
Neutrophils (109/L) 0.73 0.42-1.24 0.245 
Lymphocytes (109/L) 0.18 0.04-0.80 0.023 
Log Hs-CRP (mg/L) 1.43 0.89-2.29 0.135 
Ferritin (ng/mL) 1.00 1.00-1.00 0.743 
IL-6 > 5.5 pg/mL (vs ≤ 5.5 
pg/mL) * 
5.64 1.21-26.33 0.028 
 
Table 8.  Time-dependent predictive factors for portal vein thrombosis from univariate Cox models on 
inflammatory markers. Hs-CRP, high-sensitive C-reactive protein; IL-6, Interleukin-6; * Observed IL-6 
median value was 5.5 pg/mL.  
 
 
  HR 95% CI  P  
Interleukin-6 > 5.5 pg/mL (vs ≤ 5.5 pg/mL) *    
 Crude 5.64 1.21-26.33 0.028 
 Adjusted for NSBB 5.00 1.05-23.65 0.043 
 Adjusted for alcohol  5.55 1.18-26.00 0.030 
 Adjusted for MELD ≥ 13 5.97 1.24-28.8 0.026 
 Adjusted for spleen size 5.50 1.17-25.90 0.031 
 Adjusted for collaterals 5.63 1.20-26.47 0.029 
 Adjusted for EV 4.96 1.05-23.23 0.042 
 Adjusted for ascites 4.91 1.00-24.11 0.050 
Lymphocytes (109/L)    
 Crude 0.18 0.04-0.80 0.023 
 Adjusted for spleen size 0.19 0.04-0.87 0.033 
 
Table 9.  Multivariate Cox proportional models of predictive factors for portal vein thrombosis (PVT) 
development, adjusted for potential confounders. NSBB, Non-selective beta-blocker; MELD, Model for end-
stage liver disease; EV, Esophageal varices; * Observed Interleukin-6 median value was 5.5 pg/mL. 
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F igure 1 .  Incidence of portal vein 
thrombosis in patients with cirrhosis 
according to lymphocyte count (cut-off 
point in the median). 
 
 
Even though IL-6’s effect over PVT development was unrelated to the global set of the variables 
tested, their levels were significantly increased in patients with high-grade esophageal varices and 
in those with collaterals found in DUS (Table 10).  
 
   HR       Median IL-6 value                  
                   (pg/mL)  
                    95% CI  
P 
Esophageal varices 
                Grade <2 
                Grade ≥2 
 
 4.23                      1.55-6.4 
 6.96                    4.94-9.27 
 
 
0.048 
Spleen size (cm)* 
                < 15 
                ≥ 15 
 
 4.41                     1.55-6.19 
 6.16                    4.23-8.02 
 
 
0.4694 
Collaterals 
                 Absent 
                 Present 
 
 4.73                    3.20-5.92 
10.05                  4.92-12.60 
 
 
0.018 
Alcohol consumption 
                 No 
                 Yes 
 
 5.08                    3.32-6.4 
 9.73                    1.55-12.8 
 
 
0.127 
Antibiotic prophylaxis 
                 No 
                 Yes 
 
 5.27                    3.32-6.81 
 9.27                    1.55-74.6 
 
 
0.145 
Hs-CRP (mg/L)* 
                < 2 
                ≥ 2 
 
 1.55                     1.55-3.32 
 10.2                     8.02-12.6 
 
 
0.0001 
 
Table 10. Median Interleukin-6 (IL-6) values (pg/mL) according to patient characteristics. Hs-CRP, High-
sensitive C-reactive protein. *Cut-offs defined according the median values observed in this sample. 
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5.  HYPOTHESIS 6 
 
HYPOTHESIS AIMS RESULTS/  STUDY 
6. PVT is not related to liver 
decompensation. 
(Secondary aim of the study) 
To determine the impact of 
PVT on morbidity 
(decompensation and 
progression of liver disease) 
and mortality. 
THROMBOCIR study 
 
Table 11 .  General information concerning hypothesis 6, respective aims and correspondent study. 
 
In the large cohort of patients enrolled in the THROMBOCIR study, progression and 
decompensation of liver disease were defined in detail as expressed in the methodology section of 
the published article (186) (Appendix 3): liver disease decompensation as a composite including 
clinically detectable ascites, HE, variceal bleeding, jaundice or serum bilirubin higher than 45 
µmol/L (2.5mg/dL), and liver disease progression as a composite including any of the 
aforementioned or any of the following laboratory findings: PT < 45%, serum albumin < 28g/L, or 
serum creatinine > 115 µmol/L (1.3mg/dL). Fifty two and 39 patients progressed and 
decompensated respectively out of the 118 who were diagnosed with PVT, while 303 and 201 
patients progressed and decompensated respectively out of 1125 patients without PVT. In those 
who developed PVT and progressed and/or decompensated, 23, 5 and 24 progressed before, on the 
same day and after PVT diagnosis respectively, while 16, 5 and 19 patients decompensated before, 
on the same day or after PVT diagnosis respectively. In multivariate analysis, PVT did not impact 
liver disease progression or decompensation, irrespectively of the degree of occlusion (Table 12). 
The presence of at least medium-sized esophageal varices was significantly related to progression 
(HR=1.70; 95% CI: 1.21-2.38, P=0.002), decompensation (HR=2.60; 95% CI: 1.78-3.81, P<0.0001) 
and death (HR=2.00; 1.22-3.26, P=0.0056). Also, an increased PT correlated well to liver disease 
progression (HR=0.79; 95% CI: 0.94-0.99, P=0.002) and decompensation (HR=0.73; 95% CI: 0.63-
0.84, P<0.0001). 
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Univariable models 
unadjusted estimates 
Adjusted for basel ine 
prognostic  variables* 
Models HR 95% CI P HR 95% CI P 
Liver disease progression       
                 Partial PVT 1.58 1.02-2.45 0.04 1.51 0.73-3.14 0.27 
                 Partial or Complete PVT 1.48 0.97-2.26 0.067 1.32 0.68-2.55 0.41 
Liver disease decompensation       
                 Partial PVT 1.77 1.07-2.92 0.027 1.60 0.69-3.74 0.28 
                 Partial or Complete PVT  1.61 0.98-2.62 0.058 1.37 0.62-3.03 0.44 
 
Table 12.  Impact of portal vein thrombosis  (PVT) on liver disease progression and decompensation. 
Models of the estimation of PVT effect as time-dependent variable from Cox models stratified on 
randomization arms. *age, esophageal varices, creatinine, bilirubin, prothrombin time, albumin and body 
mass index. (Adapted from Table 3 THROMBOCIR study [186]). 
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CHAPTER V 
DISCUSSION 
 
1.  HYPOTHESES 1 ,  2  AND 3 
 
AIMS M AIN RESULTS 
1. To determine PVT risk factors related to portal 
hypertension and degree of liver failure. 
Esophageal varices ≥ grade 2 were clearly 
associated with PVT in both studies and 
increased PT in THROMBOCIR study. 
2. To determine a possible cause-effect 
relationship between decreased PBFV and PVT 
development. 
Decreased PBFV was not associated with PVT 
development, either at baseline or its decrease 
with time. 
3. To determine the relationship between NSBB 
use and PVT development. 
To find possible ways NSBB induce PVT. 
Patients on NSBB are at risk of developing PVT, 
irrespectively of their effect on a decrease in 
heart rate or in PBFV. 
 
Table 13.  Main results regarding proposed aims for the three first hypotheses. 
 
In contrast to the majority of the works conducted to date in which populations with more severe 
liver disease are usually involved, we determined risk factors for PVT development in more stable 
liver disease patients, since the THROMBOCIR study enrolled only Child-Pugh A (mostly) and B 
patients, 863 and 380, respectively, and the FRTVPCir study included a vast majority (95%) of 
Child-Pugh A and B patients, 84 and 19, respectively. In the FRTVPCir study, in the remaining and 
residual population of Child-Pugh C patients no thrombotic event was documented. This is 
important, as PVT may be seen as a non-negligible event even in less severe liver cirrhotic patients, 
since we achieved a PVT cumulative incidence of 4.6%, 8.2% and 10.7% in the 1st, 3rd and 5th years 
in THROMBOCIR and a global incidence of 10.2% in the FRTVPCir studies. Still, theses incidence 
rates are somehow lower than the ones found by Zocco et al (16.4% in the 1st year; PVT found in 12 
patients among 73 that completed follow-up)(25) and Abdel-Razik et al (17.9% in the 1st year; PVT 
found in 17 patients among 95 that completed follow-up)(89) in a mixed Child-Pugh population of 
cirrhotic patients, though, more severe ones. 
Both studies were clear in finding the presence of at least medium-sized esophageal varices as a 
risk factor for PVT, expressing a more severe state of portal hypertension. Even if some authors 
achieved the same results in a retrospective cohort (189), higher grades of esophageal varices 
were not consistently found to be particularly associated to PVT by others (25, 89). Nevertheless, 
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it is still necessary to try to establish an eventual link between this more severe portal 
hypertension state, as expressed by higher degrees of esophageal varices and related local blood 
stasis induced by a decrease in PBFV. This seems to be reasonable, as esophageal varices, being 
collaterals deviating blood from portal vein tract could, at least in theory, decrease PBFV. 
Curiously, both of our studies (186, 188) that identified esophageal varices as being predictors of 
PVT did not find PBFV as a risk factor for PVT and both other longitudinal studies that associated a 
decrease in PBFV to PVT, did not find esophageal varices size to be predictive of PVT (25, 89). 
Methodological questions must be raised, since important issues (such as standardization of 
timing and evaluation of esophageal varices before patient inclusion, those related to PVT 
evaluation, and particularities concerning the equipment used, Doppler beam incidence, 
interobserver variability, etc.) are still to be definitively resolved. 
As stated, patients with more severe liver disease are those who may be more prone to develop 
PVT (19-21, 190). The severity may be explained not only by signs of portal hypertension as 
aforementioned, but also by a deficit in liver synthesis characterized by high levels of bilirubin, 
lower levels of albumin and longer PT. Also, liver insufficiency may be “quantified” by means of 
the Child-Pugh score evaluation in which these analytical parameters taken together with ascites 
and HE are evaluated (191, 192) and by the MELD score (193) which uses, besides bilirubin and INR 
values, creatinine levels. Both the THOMBOCIR and FRTVPCir studies failed in finding any 
association between advanced Child-Pugh scores or a higher MELD grade with PVT. However, both 
studies enrolled a vast majority of patients with a more stable and not advanced liver disease, so, 
with less important deficit of synthesis. Nevertheless, THROMBOCIR, with 1243 patients, being a 
more powerful study, found that increased PT was associated with PVT (186). High MELD score 
was associated with PVT development by Zocco et al, however it lost significance in multivariate 
analysis (25). Abdel-Razik et al even settled a MELD score cut-off of 15 in which higher punctuation 
was related to PVT occurrence. Higher MELD scores may imply an acquired prothrombotic 
associated condition favoring PVT, as increased D-dimers have been found in patients with higher 
MELD scores (25, 89), as well as decreased protein C and antithrombin (25). Liver insufficiency may 
play a role in the future development of PVT, despite being weak and only seen in powerful 
studies, and probably associated to related acquired prothrombotic condition. 
Portal blood flow velocity decreases with the increased severity of liver failure expressed by higher 
Child-Pugh scores (130) and has also been associated to decreased survival (132). As PVT is 
expected to be more prevalent among the severest cirrhotic patients, if a decreased PBFV is 
expected in these patients, PVT would be therefore explained by this mechanism. Zocco et al (25) 
and Abdel Razik et al (89) found an association between reduced PBFV (< 15cm/s) at baseline and 
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future PVT development. These findings were recently supported by a retrospective case-control 
study matched for age, gender and MELD score, in which for each decrease of 1 cm/s in PBFV less 
than 15cm/s there was a 6-times higher risk of developing PVT (43). However, a decreased PBFV 
was not always found to be associated to PVT (90). THROMBOCIR (186) and FRTVPCir (188) 
studies failed in establishing a relationship between lower PBFV and increased risk for PVT 
development. THROMBOCIR is to date the most powerful study involving the largest cohort of 
patients. Different operators with different equipment in the 43 centers involved may add some 
fragility to the data. However, in order to diminish associated confusing factors, the operator and 
equipment used was always the same in the follow-up of each one of the patients and PBFV was 
seen as a time-dependent variable, strengthening our results (186). FRTVPCir followed a similar 
methodology as the one adopted by Zocco et al (25), with all the Doppler measurements validated 
by a senior (and always the same) radiologist consultant (188). We cannot conclude, based on our 
findings in both studies an independent relationship between PBFV and PVT, which means that 
this is not a settled issue and standardization of methodologies that involve same fasting periods, 
equipment, incidence beams and validation by other operators must be considered in future 
investigations. Other methods of measuring PBFV other than by DUS that can be reproduced and 
validated by others should be considered in future works such as, for, example, four-dimensional 
flow magnetic resonance (194). 
Non-selective beta-blockers are commonly used for primary and secondary prophylaxis of variceal 
bleeding (10). Their risk for PVT development was proposed some years ago due to a possible 
effect on lowering PBFV (136). Pellicelli et al, in an unpublished study found an association 
between NSBB use and PVT (137). Two recent retrospective studies also achieved similar results, 
but no information concerning time under treatment, dose used, and hemodynamic aspects were 
considered (189, 195). We found that NSBB were related to PVT occurrence, this effect being more 
pronounced in FRTVPCir (188) than in THROMBOCIR (186). The FRTVPCir study is, to date, the only 
prospectively conducted study that specifically addressed this problematic and tried to find the 
mechanisms by which NSBB could be related to PVT development. We clearly documented, in 
patients under NSBB treatment, not only a reduction in PBFV but in heart rate as well. Contrary to 
what was expected, these effects by NSBB use did not justify PVT, thus the underlying mechanism 
remains unknown. The administered dose of NSBB also was not related to PVT even though a 
tendency towards higher doses was found (188). Nevertheless, older studies found that patients 
with cirrhosis had an enhanced sympathetic nervous system activity in relation to the severity of 
the liver disease (196, 197). Valla et al found that in patients injected with propranolol (a NSBB), 
subsequent infusion of adrenalin led to further decrease in azygos blood flow (198). This means 
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that in patients with cirrhosis under NSBB therapy an additive and enhanced effect of 
catecholamines released by an already activated sympathetic nervous system, which could be in 
proportion to the severity of the liver disease, could lead to further hemodynamic disturbance 
helping to justify the implication of NSBB therapy on PVT development and probably in identifying 
patients in which NSBB should not be used. This is an important issue to be addressed in future 
studies since NSBB are widely used in patients with cirrhosis. 
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2.  HYPOTHESIS 4 
 
AIMS M AIN RESULTS 
4. To determine FVL and PTHR gene mutations 
and to settle competing risk for PVT 
development. 
No risk attributed to the presence of FVL, PTHR 
gene mutations, or both, and PVT development 
was found. 
 
Table 14.  Main results regarding proposed aims for the fourth hypothesis. 
 
Current guidelines advise the screening of genetic conditions favoring thrombosis, namely the 
presence of FVL and PTHR gene mutations for patients with cirrhosis, diagnosed with PVT (7, 10). 
In the THROMBOCIR analyzed population, only 5% and 3% of the patients revealed positivity for 
FVL and PTHR gene mutations respectively, all but one (FVL mutation) in heterozygosity, which 
was not related to an incremented risk for PVT development (186). Our data is approached to the 
prevalence of both mutations in the general French population without any thrombotic event 
(199). The relationship between the presence of these two mutations and an increased risk for PVT 
development in cirrhosis has not been clearly settled, with even meta-analysis (109, 110), revealing 
conflicting results among studies. We found other risk factors to be more important than the 
genetic ones that, in the context of cirrhosis, predispose patients to PVT. 
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3.  HYPOTHESIS 5 
 
AIMS M AIN RESULTS 
5. To determine inflammatory markers 
(leukocytes, Hs-CRP, ferritin, TNF-α, IL-6) and 
related risk for PVT. 
Increased IL-6 levels and decreased lymphocyte 
count at baseline predicted PVT development. 
Interleukin-6 levels were elevated in patients 
with some features of more severe portal 
hypertension (higher esophageal varices grade 
and presence of collaterals). 
 
Table 15.  Main results regarding proposed aims for the fifth hypothesis. 
 
No study has specifically addressed the issue of inflammation and related PVT risk in patients with 
cirrhosis. The scarce data is extracted from published papers mainly as secondary outcomes. 
We found that a low lymphocyte count at baseline was related to future PVT occurrence, with a 6-
times higher risk when below the cut-off value of 1.2 x 109/L. We also found a trend to a decrease 
in lymphocyte count with time in all patients, more evident in those developing PVT, even if 
without statistical meaning. Vascular inflammation, as a result of the interaction between 
platelets and leucocytes on the activated endothelium (via multiple signalling pathways) may be 
responsible for microvascular occlusion in many vascular beds (200). In the liver, leucocyte 
adhesion to the hepatic sinusoidal endothelium is enhanced by platelet binding, namely of 
lymphocytes mediated by the secretion of CCL2 nuclear factor-κB-dependent (201). Theoretically, 
this lymphocyte migration/ homing may explain a reduction in their peripheral count, local 
sinusoidal inflammation and subsequent microvascular occlusion. Thus, lymphopenia could be a 
marker of a homing effect reflecting local inflammation and by this mean a propensity to 
thrombosis. However, a direct thrombotic effect of a lower lymphocyte count on any vascular bed 
is unknown. Curiously, platelet binding to the vascular endothelium has been observed in a larger 
extent in the portal tract than in the sinusoids (201). Lymphocyte homing to the liver may be 
explained by this mechanism, but they may also home directly to the spleen in a direct relation to 
its size reflecting, once again, a higher degree of portal hypertension. However, the action of low 
lymphocyte count over PVT development was unrelated, in our cohort, to an increase in spleen 
size. This is currently an open field research issue to be addressed. 
Endotoxin levels have been found to be related to the severity of cirrhosis (166) and the severity of 
cirrhosis to increased circulating IL-6 (202). Also, in a recent cross-sectional study, IL-6 was found 
to be related to not only to poorer liver function, but also to more severe grades of esophageal 
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varices and even to mortality (203). Only Villa et al in her study addressing specifically the safety 
and efficacy of enoxaparin in PVT prevention in patients with Child-Pugh B7-C10 cirrhosis 
evaluated the immune response to bacterial translocation dosing, among others, IL-6 (24). She 
found increased IL-6 levels in patients with higher soluble CD14 levels (a marker of host response 
to microbial products, namely LPS), this last being related to PVT development (P=0.030) (24). 
Unfortunately no results are presented concerning IL-6 relationship to PVT. We present the first 
study that found a close relation between higher IL-6 levels and PVT occurrence. Even though IL-6 
levels increased with the severity of esophageal varices size (validating the results achieved by Kao 
et al [203]) and other markers of portal hypertension such as the presence of collaterals, its effect 
over PVT is beyond the one related to these features of portal hypertension and eventual local 
blood stasis, which may be linked to local endothelial dysfunction. Another way to justify the 
association between IL-6 and PVT is by an increased synthesis of VWF by the endothelial cell 
which is known to be induced by IL-6, favoring, in this way, thrombosis (157, 158). 
Other inflammatory markers tested were not related to future PVT occurrence. Concerning C-
reactive protein, only Abdel Razik et al and Chen et al longitudinally tested this association, which 
was null (89, 90). We used, as Chen et al (90), Hs-CRP, which is more sensitive than the standard 
test. Even though their levels increased in proportion to IL-6 (Table 10), as expected due to the 
fact that it is produced after IL-6 signaling (204), they were not found to be related to PVT. This 
may be explained by an increased sensitivity of IL-6 as an inflammatory marker than Hs-CRP in 
patients with cirrhosis, already documented by Le Moine et al that showed a bad correlation 
between these both markers revealing a defective acute-phase response in cirrhosis (205). Also, 
while being mainly produced in the liver (204), C-reactive protein is not found to be a good marker 
of inflammation in the setting of cirrhosis. This is corroborated by the work of Park et al who 
disclosed that in the context of a more severe liver disease, C-reactive protein response to 
bacteremia is decreased (206). 
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4.  HYPOTHESIS 6 
 
AIMS M AIN RESULTS 
6. (Secondary aim of the study). To determine 
the impact of PVT on morbidity 
(decompensation and progression of liver 
disease) and mortality. 
Portal vein thrombosis, either partial or 
occlusive is not related to increased morbid-
mortality. Decompensation and PVT share some 
same risk factors. 
 
Table 16.  Main results regarding proposed aims for the sixth hypothesis. 
 
Increased post-LT early-mortality is well established in those patients with PVT submitted to this 
surgical procedure (53). Also, historically and in cross-sectional studies, decompensation and 
progression of the underlying liver disease has been attributed to PVT, as both diagnoses (PVT and 
decompensation) were done at the same time (19, 23). In the THROMBOCIR study, there were 
patients with PVT that decompensated and progressed after the event, patients without PVT 
having the same outcome and without PVT that also decompensated and progressed. In the end, 
in multivariate analysis we did not find any parallel between PVT occurrence irrespectively of 
being partial or occlusive and decompensation or liver disease progression. We also did not find 
any relationship with an increased mortality. However, we found that PVT and decompensation 
and progression shared exactly the same risk factors as the presence of at least medium-sized 
esophageal varices and increased PT favoring the hypothesis that they may reflect the same 
expression of a more severe liver disease. Our results go in line and prospectively validate recent 
previous longitudinal studies (33, 35). We also found an outstanding variability on the course of 
PVT with time without anticoagulation, with almost 70% of the patients spontaneously resolving 
PVT (186). We validated in the largest cohort of patients, a tendency, previously reported, in which 
this dynamic characteristic of PVT without treatment was already perceived (33-35). Nevertheless 
these results should be viewed with caution, as anticoagulation at prophylactic doses may change 
the clinical course, with impact in decompensation and survival. Villa et al well documented that 
patients under enoxaparin in prophylactic doses (40mg/ day) decreased the probability not only 
of developing PVT but also decompensation and mortality (24). The improvement of 
microcirculation/ decrease in microthrombi induced by enoxaparin treatment with a decrease in 
bacterial translocation and improvement in endothelial function is an advanced hypothesis to 
justify the positive results achieved (24). Accordingly, our findings, altogether showing the 
potential of reversibility of PVT once diagnosed without treatment and the minor impact in 
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morbid-mortality out of the LT setting, together with the ones by Villa et al (24) are important in 
order to design future studies with the aim to settle which subtypes of patients benefit most from 
anticoagulation treatment, either in prophylactic or in therapeutic doses. It is however important 
to mention that a beneficial effect of anticoagulation treatment seems to exist, as recent 
evidence presented in a robust meta-analysis, shows that PVT resolves more often with no more 
bleeding events noticed, with a decline in the episodes of variceal bleeding in those patients under 
anticoagulation (207). 
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CHAPTER VI 
CONCLUSIONS 
 
We have identified some new risk factors for PVT development and validated others in two 
independent cohorts. Markers of more severe portal hypertension (presence of esophageal varices 
grade ≥ 2), liver insufficiency (as expressed by prolonged PT) and inflammatory status (revealed by 
higher titers of IL-6) were found to be associated to future PVT development in the studies. Liver 
insufficiency may ultimately be related to a hypercoagulable state and increased inflammation to 
endothelial dysfunction, fundamental pillars of Virchow’s triad to explain thrombotic 
phenomena. More inflamed patients were also those with more severe grades of portal 
hypertension. No relationship between decreased PBFV and PVT was found. Non-selective beta-
blockers induced PVT independently from their effect over heart rate or PBFV. Portal vein 
thrombosis and liver disease progression and decompensation share of the same risk factors but 
there does not seem to be a causal relationship between the two. Portal vein thrombosis is more a 
marker than a promoter of liver disease progression or decompensation and both events may 
occur together in the course of the disease unrelated to each other. 
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CHAPTER VII  
CLINICAL IMPLICATIONS AND FUTURE PERSPECTIVES 
 
The results that we achieved with both studies allowed us to document that PVT is a non-
negligible event in cirrhosis, even in more stable patients, such as those with Child-Pugh A and B 
liver insufficiency, affecting about 1 in every 10 patients. Regular screening programs for PVT 
diagnosis do not exist as for HCC out of the context of LT. We have not only found an absent 
relationship between PVT and liver disease decompensation, progression or death, but also a high 
rate of spontaneous repermeabilization of the portal vein or its branches after the thrombotic 
event, which is why based solely on these results, we cannot propose a regular PVT screening 
program. However, given the discovered incidences, there must be awareness concerning PVT 
diagnosis in stable cirrhotic patients among physicians. Nevertheless, we found that PVT and liver 
decompensation share some of the same risk factors, which may, together with the results 
advanced by Villa et al (24) allow us to determine, in the future, subgroups of patients in which 
risk factors, being identified, may determine which patients shall benefit most and be the target 
of prophylactically therapeutic measures. Parameters related to increased portal hypertension 
such as the ones related to the presence of at least medium-sized esophageal varices in both 
studies and to some degree of liver insufficiency settled by increased PT in THROMBOCIR are 
related both to PVT and to liver decompensation. We also found an association between NSBB use 
and PVT. This is of major importance, because i) their use is advised for primary and secondary 
prophylaxis of variceal bleeding (10); ii) they were found to negatively impact survival in patients 
with more advanced liver disease such as those with Child-Pugh C and refractory ascites (208). 
Thus, even though there is clear indication for this therapeutic class of drugs, a subgroup of 
patients exists in which its use is deleterious, which means that NSBB use should not be 
generalized. The future validation of our results will imply a change in the strategy concerning the 
selection of patients that undergo ligature of esophageal varices even in the setting of primary 
prophylaxis. We also found lymphopenia and IL-6 as markers for PVT development. For the first 
time, an increased inflammatory milieu has been recognized to predispose patients to PVT 
development, adding to the preexisting knowledge of Virchow’s triad, the third pillar related to 
endothelial dysfunction. If measures to decontaminate gut in order to diminish bacterial 
translocation, anti-inflammatory therapeutic strategies, prophylactically anticoagulation, etc. are 
effective in decreasing inflammation and subsequently improve endothelial dysfunction in this 
context and prevent PVT development is yet to be determined. 
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One of the goals of research is not only to give new knowledge to science and current state of the 
art, but also to give raise to new fields of investigation in order to try to answer raised unmet 
questions. There are several issues that must now be clarified in future works: 
 
I) To address if higher degrees of esophageal varices inversely relates to PBFV; 
ii) To find by which means liver insufficiency, translated by increased bilirubin, extended 
coagulation times/ decreased coagulation factors or decreased albumin may lead to PVT, 
probably relating to an acquired prothrombotic condition due to failure in producing 
anticoagulants and procoagulants in right proportion; 
iii) To find local hemodynamic aspects that may promote PVT in patients under NSBB; 
iv) To find the subgroup of patients that would benefit most of NSBB treatment without an 
increased risk of PVT development; 
v) To search for lymphocyte homing mechanisms for the liver, spleen and eventually other organs 
in the context of cirrhosis and if this mechanism is implicated in the enhancement of endothelial 
inflammation and more propensity to thrombosis; 
vi) To establish a link between endotoxemia, IL-6 levels and PVT and to try to find the way IL-6 
induces PVT, namely via downregulation of thrombomodulin (reflecting LPS levels) or endothelial 
synthesis of VWF; 
vii) To find possible new therapeutic strategies in order to avoid PVT development, namely in 
patients awaiting LT (prophylactically anticoagulation, anti-inflammatory and gut 
decontaminating therapeutics, etc.); 
vii) To create a predictive score for PVT development in patients with cirrhosis. 
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Appendix 1 
Splanchnic and Extrasplanchnic Thrombosis  in  Cirrhosis:  Prophylaxis  vs  
Treatment.  
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Appendix 2 
Towards a Comprehensive New Classif ication of Portal  Vein Thrombosis  in  
Patients With Cirrhosis.  
Sarin SK, Philips CA, Kamath PS, Choudhury A, Maruyama H, Nery FG, Valla DC. 
Gastroenterology. 2016 Oct; 151(4): 574-577.e3. 
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Appendix 3 
Causes and consequences of portal  vein thrombosis  in  1 ,243 patients with 
cirrhosis:  results  of  a  longitudinal  study. 
Nery F, Chevret S, Condat B, de Raucourt E, Boudaoud L, Rautou PLE, Plessier A, Roulot D, 
Chaffaut C, Bourcier V, Trinchet JC, Valla DC, Groupe d’Etude et de Traitment du 
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Appendix 4 
Nonselective beta-blockers and r isk of  portal  vein thrombosis  in  patients 
with c irrhosis:  results of  a  prospective longitudinal  study.  
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MT, Lucas R, Rautou PE, Miranda HP, Valla D. Aliment Pharmacol Ther. 2019 Jan. 
Doi: 10.1111/apt.15137. Epub ahead of print 
 
 
 
  
APPENDICES 	  
	  106 
 
APPENDICES 
	   107 
 
APPENDICES 	  
	  108 
 
APPENDICES 
	   109 
 
APPENDICES 	  
	  110 
 
APPENDICES 
	   111 
 
APPENDICES 	  
	  112 
 
APPENDICES 
	   113 
 
APPENDICES 	  
	  114 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 	   115 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
REFERENCES 
  
	  	  116 
  
REFERENCES 
	   117 
REFERENCES 
 
 
1. Patel K, Bedossa P, Castera L. Diagnosis of liver fibrosis: present and future. Seminars in 
liver disease. 2015;35(2):166-83. 
2. Asrani SK, Devarbhavi H, Eaton J, Kamath PS. Burden of Liver Diseases in the World. 
Journal of hepatology. 2018. 
3. Lim YS, Kim WR. The global impact of hepatic fibrosis and end-stage liver disease. Clinics 
in liver disease. 2008;12(4):733-46, vii. 
4. D'Amico G, Garcia-Tsao G, Pagliaro L. Natural history and prognostic indicators of survival 
in cirrhosis: a systematic review of 118 studies. Journal of hepatology. 2006;44(1):217-31. 
5. European Association for the Study of the Liver. Electronic address eee, European 
Association for the Study of the L. EASL Clinical Practice Guidelines for the management of 
patients with decompensated cirrhosis. Journal of hepatology. 2018;69(2):406-60. 
6. European Association for the Study of the Liver. Electronic address eee, European 
Association for the Study of the L. EASL Clinical Practice Guidelines: Management of 
hepatocellular carcinoma. Journal of hepatology. 2018;69(1):182-236. 
7. European Association for the Study of the Liver. Electronic address eee. EASL Clinical 
Practice Guidelines: Vascular diseases of the liver. Journal of hepatology. 2016;64(1):179-202. 
8. Rafailidis V, Fang C, Yusuf GT, Huang DY, Sidhu PS. Contrast-enhanced ultrasound (CEUS) 
of the abdominal vasculature. Abdominal radiology. 2018;43(4):934-47. 
9. Nery F, Valla D. Splanchnic and extrasplanchnic thrombosis in cirrhosis: prophylaxis vs 
treatment. Curr Hepatology Rep 2014;13:224-34. 
10. de Franchis R, Baveno VIF. Expanding consensus in portal hypertension: Report of the 
Baveno VI Consensus Workshop: Stratifying risk and individualizing care for portal hypertension. 
Journal of hepatology. 2015;63(3):743-52. 
11. Hunt AH WB. Thrombosis of the portal vein in cirrhosis hepatis. Lancet. 
1954;263(6806):281-4. 
12. Hou PC, McFadzean AJ. Thrombosis and Intimal Thickening in the Portal System in 
Cirrhosis of the Liver. The Journal of pathology and bacteriology. 1965;89:473-80. 
13. Okuda K, Ohnishi K, Kimura K, Matsutani S, Sumida M, Goto N, et al. Incidence of portal 
vein thrombosis in liver cirrhosis. An angiographic study in 708 patients. Gastroenterology. 
1985;89(2):279-86. 
REFERENCES 	  
	  118 
14. Dye WS, David D, Julian OC. Successful treatment of portal vein thrombosis associated 
with intrahepatic obstruction. Archives of surgery. 1960;80:876-82. 
15. Coomaraswamy RP, Delguercio LR, Miller H, State D, Elkin M. Splenoportography and 
Portal Vein Thrombosis in Patients with Cirrhosis of the Liver. Surgery, gynecology & obstetrics. 
1964;118:560-6. 
16. Sicot C, Sakellaridis D, Rueff B, Maillard JN, Benhamou JP. Portal vin thrombosis in 
intrahepatic block. Minnesota medicine. 1971;54(2):87-90. 
17. Sarfeh IJ. Portal vein thrombosis associated with cirrhosis: clinical importance. Archives of 
surgery. 1979;114(8):902-5. 
18. Belli L, Romani F, Sansalone CV, Aseni P, Rondinara G. Portal thrombosis in cirrhotics. A 
retrospective analysis. Annals of surgery. 1986;203(3):286-91. 
19. Nonami T, Yokoyama I, Iwatsuki S, Starzl TE. The incidence of portal vein thrombosis at 
liver transplantation. Hepatology. 1992;16(5):1195-8. 
20. Gayowski TJ, Marino IR, Doyle HR, Echeverri L, Mieles L, Todo S, et al. A high incidence of 
native portal vein thrombosis in veterans undergoing liver transplantation. The Journal of surgical 
research. 1996;60(2):333-8. 
21. Manzanet G, Sanjuan F, Orbis P, Lopez R, Moya A, Juan M, et al. Liver transplantation in 
patients with portal vein thrombosis. Liver transplantation : official publication of the American 
Association for the Study of Liver Diseases and the International Liver Transplantation Society. 
2001;7(2):125-31. 
22. Francoz C, Belghiti J, Vilgrain V, Sommacale D, Paradis V, Condat B, et al. Splanchnic vein 
thrombosis in candidates for liver transplantation: usefulness of screening and anticoagulation. 
Gut. 2005;54(5):691-7. 
23. Amitrano L, Guardascione MA, Brancaccio V, Margaglione M, Manguso F, Iannaccone L, et 
al. Risk factors and clinical presentation of portal vein thrombosis in patients with liver cirrhosis. 
Journal of hepatology. 2004;40(5):736-41. 
24. Villa E, Camma C, Marietta M, Luongo M, Critelli R, Colopi S, et al. Enoxaparin prevents 
portal vein thrombosis and liver decompensation in patients with advanced cirrhosis. 
Gastroenterology. 2012;143(5):1253-60 e1-4. 
25. Zocco MA, Di Stasio E, De Cristofaro R, Novi M, Ainora ME, Ponziani F, et al. Thrombotic 
risk factors in patients with liver cirrhosis: correlation with MELD scoring system and portal vein 
thrombosis development. Journal of hepatology. 2009;51(4):682-9. 
26. Stieber AC, Zetti G, Todo S, Tzakis AG, Fung JJ, Marino I, et al. The spectrum of portal vein 
thrombosis in liver transplantation. Annals of surgery. 1991;213(3):199-206. 
REFERENCES 
	   119 
27. Ma J, Yan Z, Luo J, Liu Q, Wang J, Qiu S. Rational classification of portal vein thrombosis 
and its clinical significance. PloS one. 2014;9(11):e112501. 
28. Jamieson NV. Changing perspectives in portal vein thrombosis and liver transplantation. 
Transplantation. 2000;69(9):1772-4. 
29. Yerdel MA, Gunson B, Mirza D, Karayalcin K, Olliff S, Buckels J, et al. Portal vein 
thrombosis in adults undergoing liver transplantation: risk factors, screening, management, and 
outcome. Transplantation. 2000;69(9):1873-81. 
30. Bauer J, Johnson S, Durham J, Ludkowski M, Trotter J, Bak T, et al. The role of TIPS for portal 
vein patency in liver transplant patients with portal vein thrombosis. Liver transplantation : 
official publication of the American Association for the Study of Liver Diseases and the 
International Liver Transplantation Society. 2006;12(10):1544-51. 
31. Sarin SK, Philips CA, Kamath PS, Choudhury A, Maruyama H, Nery FG, et al. Toward a 
Comprehensive New Classification of Portal Vein Thrombosis in Patients With Cirrhosis. 
Gastroenterology. 2016;151(4):574-7 e3. 
32. Laws JW, Leigh R, Steiner RE. Extra hepatic portal vein obstruction. The British journal of 
radiology. 1959;32:774-90. 
33. Luca A, Caruso S, Milazzo M, Marrone G, Mamone G, Crino F, et al. Natural course of 
extrahepatic nonmalignant partial portal vein thrombosis in patients with cirrhosis. Radiology. 
2012;265(1):124-32. 
34. Maruyama H, Okugawa H, Takahashi M, Yokosuka O. De novo portal vein thrombosis in 
virus-related cirrhosis: predictive factors and long-term outcomes. The American journal of 
gastroenterology. 2013;108(4):568-74. 
35. John BV, Konjeti R, Aggarwal A, Lopez R, Atreja A, Miller C, et al. Impact of untreated 
portal vein thrombosis on pre and post liver transplant outcomes in cirrhosis. Annals of 
hepatology. 2013;12(6):952-8. 
36. Wanless IR, Wong F, Blendis LM, Greig P, Heathcote EJ, Levy G. Hepatic and portal vein 
thrombosis in cirrhosis: possible role in development of parenchymal extinction and portal 
hypertension. Hepatology. 1995;21(5):1238-47. 
37. Anstee QM, Wright M, Goldin R, Thursz MR. Parenchymal extinction: coagulation and 
hepatic fibrogenesis. Clinics in liver disease. 2009;13(1):117-26. 
38. Bilodeau M, Aubry MC, Houle R, Burnes PN, Ethier C. Evaluation of hepatocyte injury 
following partial ligation of the left portal vein. Journal of hepatology. 1999;30(1):29-37. 
REFERENCES 	  
	  120 
39. Farges O, Belghiti J, Kianmanesh R, Regimbeau JM, Santoro R, Vilgrain V, et al. Portal vein 
embolization before right hepatectomy: prospective clinical trial. Annals of surgery. 
2003;237(2):208-17. 
40. Kusaka K, Imamura H, Tomiya T, Takayama T, Makuuchi M. Expression of transforming 
growth factor-alpha and -beta in hepatic lobes after hemihepatic portal vein embolization. 
Digestive diseases and sciences. 2006;51(8):1404-12. 
41. Lautt WW, Legare DJ, Ezzat WR. Quantitation of the hepatic arterial buffer response to 
graded changes in portal blood flow. Gastroenterology. 1990;98(4):1024-8. 
42. Jakab F, Rath Z, Schmal F, Nagy P, Faller J. The interaction between hepatic arterial and 
portal venous blood flows; simultaneous measurement by transit time ultrasonic volume 
flowmetry. Hepato-gastroenterology. 1995;42(1):18-21. 
43. Stine JG, Wang J, Shah PM, Argo CK, Intagliata N, Uflacker A, et al. Decreased portal vein 
velocity is predictive of the development of portal vein thrombosis: A matched case-control 
study. Liver international : official journal of the International Association for the Study of the 
Liver. 2018;38(1):94-101. 
44. Englesbe MJ, Schaubel DE, Cai S, Guidinger MK, Merion RM. Portal vein thrombosis and 
liver transplant survival benefit. Liver transplantation : official publication of the American 
Association for the Study of Liver Diseases and the International Liver Transplantation Society. 
2010;16(8):999-1005. 
45. Berry K, Taylor J, Liou IW, Ioannou GN. Portal vein thrombosis is not associated with 
increased mortality among patients with cirrhosis. Clinical gastroenterology and hepatology : the 
official clinical practice journal of the American Gastroenterological Association. 2015;13(3):585-
93. 
46. Qi X, Dai J, Yang M, Ren W, Jia J, Guo X. Association between Portal Vein Thrombosis and 
Survival in Non-Liver-Transplant Patients with Liver Cirrhosis: A Systematic Review of the 
Literature. Gastroenterology research and practice. 2015;2015:480842. 
47. Ferreira C.N. RT, Alexandrino P., Ramalho F., Velosa J.F. Portal vein thrombosis in cirrhotic 
patients is associated with advanced liver disease and predicts poor long term prognosis. 
Hepatology. 2010;52(article 1072A). 
48. Dumortier J, Czyglik O, Poncet G, Blanchet MC, Boucaud C, Henry L, et al. Eversion 
thrombectomy for portal vein thrombosis during liver transplantation. American journal of 
transplantation : official journal of the American Society of Transplantation and the American 
Society of Transplant Surgeons. 2002;2(10):934-8. 
REFERENCES 
	   121 
49. Llado L, Fabregat J, Castellote J, Ramos E, Torras J, Jorba R, et al. Management of portal 
vein thrombosis in liver transplantation: influence on morbidity and mortality. Clinical 
transplantation. 2007;21(6):716-21. 
50. Tao YF, Teng F, Wang ZX, Guo WY, Shi XM, Wang GH, et al. Liver transplant recipients with 
portal vein thrombosis: a single center retrospective study. Hepatobiliary & pancreatic diseases 
international : HBPD INT. 2009;8(1):34-9. 
51. Ravaioli M, Zanello M, Grazi GL, Ercolani G, Cescon M, Del Gaudio M, et al. Portal vein 
thrombosis and liver transplantation: evolution during 10 years of experience at the University of 
Bologna. Annals of surgery. 2011;253(2):378-84. 
52. Englesbe MJ, Kubus J, Muhammad W, Sonnenday CJ, Welling T, Punch JD, et al. Portal vein 
thrombosis and survival in patients with cirrhosis. Liver transplantation : official publication of the 
American Association for the Study of Liver Diseases and the International Liver Transplantation 
Society. 2010;16(1):83-90. 
53. Ghabril M, Agarwal S, Lacerda M, Chalasani N, Kwo P, Tector AJ. Portal Vein Thrombosis Is 
a Risk Factor for Poor Early Outcomes After Liver Transplantation: Analysis of Risk Factors and 
Outcomes for Portal Vein Thrombosis in Waitlisted Patients. Transplantation. 2016;100(1):126-33. 
54. Montenovo M, Rahnemai-Azar A, Reyes J, Perkins J. Clinical Impact and Risk Factors of 
Portal Vein Thrombosis for Patients on Wait List for Liver Transplant. Experimental and clinical 
transplantation : official journal of the Middle East Society for Organ Transplantation. 2017. 
55. Qi X, Dai J, Jia J, Ren W, Yang M, Li H, et al. Association between portal vein thrombosis and 
survival of liver transplant recipients: a systematic review and meta-analysis of observational 
studies. Journal of gastrointestinal and liver diseases : JGLD. 2015;24(1):51-9, 4 p following 9. 
56. Zanetto A, Rodriguez-Kastro KI, Germani G, Ferrarese A, Cillo U, Burra P, et al. Mortality in 
liver transplant recipients with portal vein thrombosis - an updated meta-analysis. Transplant 
international : official journal of the European Society for Organ Transplantation. 2018;31(12):1318-
29. 
57. Lendoire J, Raffin G, Cejas N, Duek F, Barros Schelotto P, Trigo P, et al. Liver 
transplantation in adult patients with portal vein thrombosis: risk factors, management and 
outcome. HPB : the official journal of the International Hepato Pancreato Biliary Association. 
2007;9(5):352-6. 
58. Ponziani FR, Zocco MA, Senzolo M, Pompili M, Gasbarrini A, Avolio AW. Portal vein 
thrombosis and liver transplantation: implications for waiting list period, surgical approach, early 
and late follow-up. Transplantation reviews. 2014;28(2):92-101. 
REFERENCES 	  
	  122 
59. Bagot CN, Arya R. Virchow and his triad: a question of attribution. British journal of 
haematology. 2008;143(2):180-90. 
60. Weeder PD, Porte RJ, Lisman T. Hemostasis in liver disease: implications of new concepts 
for perioperative management. Transfusion medicine reviews. 2014;28(3):107-13. 
61. Hugenholtz GG, Porte RJ, Lisman T. The platelet and platelet function testing in liver 
disease. Clinics in liver disease. 2009;13(1):11-20. 
62. Bashour FN, Teran JC, Mullen KD. Prevalence of peripheral blood cytopenias 
(hypersplenism) in patients with nonalcoholic chronic liver disease. The American journal of 
gastroenterology. 2000;95(10):2936-9. 
63. Qamar AA, Grace ND, Groszmann RJ, Garcia-Tsao G, Bosch J, Burroughs AK, et al. 
Incidence, prevalence, and clinical significance of abnormal hematologic indices in compensated 
cirrhosis. Clinical gastroenterology and hepatology : the official clinical practice journal of the 
American Gastroenterological Association. 2009;7(6):689-95. 
64. Afdhal N, McHutchison J, Brown R, Jacobson I, Manns M, Poordad F, et al. 
Thrombocytopenia associated with chronic liver disease. Journal of hepatology. 2008;48(6):1000-
7. 
65. Hypersplenism. California medicine. 1973;118(1):24-9. 
66. Yanaga K, Tzakis AG, Shimada M, Campbell WE, Marsh JW, Stieber AC, et al. Reversal of 
hypersplenism following orthotopic liver transplantation. Annals of surgery. 1989;210(2):180-3. 
67. Latorre R, Vaquero J, Rincon D, Puerto M, Ponce MD, Sarnago F, et al. Determinants of 
platelet count are different in patients with compensated and decompensated cirrhosis. Liver 
international : official journal of the International Association for the Study of the Liver. 2015. 
68. Koruk M, Onuk MD, Akcay F, Savas MC. Serum thrombopoietin levels in patients with 
chronic hepatitis and liver cirrhosis, and its relationship with circulating thrombocyte counts. 
Hepato-gastroenterology. 2002;49(48):1645-8. 
69. Panasiuk A, Prokopowicz D. Platelet autoantibodies in liver cirrhosis and 
thrombocytopenia. Roczniki Akademii Medycznej w Bialymstoku. 2000;45:54-62. 
70. Pradella P, Bonetto S, Turchetto S, Uxa L, Comar C, Zorat F, et al. Platelet production and 
destruction in liver cirrhosis. Journal of hepatology. 2011;54(5):894-900. 
71. Christodoulou D, Katsanos K, Zervou E, Theopistos V, Papathanasopoulos A, Christou L, et 
al. Platelet IgG antibodies are significantly increased in chronic liver disease. Annals of 
gastroenterology : quarterly publication of the Hellenic Society of Gastroenterology. 2011;24(1):47-
52. 
REFERENCES 
	   123 
72. Ferro D, Quintarelli C, Lattuada A, Leo R, Alessandroni M, Mannucci PM, et al. High plasma 
levels of von Willebrand factor as a marker of endothelial perturbation in cirrhosis: relationship to 
endotoxemia. Hepatology. 1996;23(6):1377-83. 
73. Lisman T, Bongers TN, Adelmeijer J, Janssen HL, de Maat MP, de Groot PG, et al. Elevated 
levels of von Willebrand Factor in cirrhosis support platelet adhesion despite reduced functional 
capacity. Hepatology. 2006;44(1):53-61. 
74. Ferlitsch M, Reiberger T, Hoke M, Salzl P, Schwengerer B, Ulbrich G, et al. von Willebrand 
factor as new noninvasive predictor of portal hypertension, decompensation and mortality in 
patients with liver cirrhosis. Hepatology. 2012;56(4):1439-47. 
75. Mannucci PM, Canciani MT, Forza I, Lussana F, Lattuada A, Rossi E. Changes in health and 
disease of the metalloprotease that cleaves von Willebrand factor. Blood. 2001;98(9):2730-5. 
76. Tornai I, Papp M, Udvardy ML, Orosz P, Harsfalvi J. The alterations on Von Willebrand 
Factor and its cleaving protease, ADAMTS-13 show an opposite change of direction in patients 
with liver cirrhosis. Journal of hepatology. 2008;48(Supplement 2):S106. 
77. Tripodi A, Primignani M, Chantarangkul V, Clerici M, Dell'Era A, Fabris F, et al. Thrombin 
generation in patients with cirrhosis: the role of platelets. Hepatology. 2006;44(2):440-5. 
78. Dooley JS, Lok ASF, Burroughs AK, Heathcote EJ. Sherlock's diseases of the liver and biliary 
system. 12th ed: Wiley-Blackwell; 2011. 
79. Tripodi A, Chantarangkul V, Mannucci PM. Acquired coagulation disorders: revisited using 
global coagulation/anticoagulation testing. British journal of haematology. 2009;147(1):77-82. 
80. Tripodi A, Primignani M, Chantarangkul V, Dell'Era A, Clerici M, de Franchis R, et al. An 
imbalance of pro- vs anti-coagulation factors in plasma from patients with cirrhosis. 
Gastroenterology. 2009;137(6):2105-11. 
81. Tripodi A, Primignani M, Lemma L, Chantarangkul V, Dell'Era A, Iannuzzi F, et al. Detection 
of the imbalance of procoagulant versus anticoagulant factors in cirrhosis by a simple laboratory 
method. Hepatology. 2010;52(1):249-55. 
82. Tripodi A, Primignani M, Lemma L, Chantarangkul V, Mannucci PM. Evidence that low 
protein C contributes to the procoagulant imbalance in cirrhosis. Journal of hepatology. 
2013;59(2):265-70. 
83. Hollestelle MJ, Geertzen HG, Straatsburg IH, van Gulik TM, van Mourik JA. Factor VIII 
expression in liver disease. Thrombosis and haemostasis. 2004;91(2):267-75. 
84. Tripodi A, Mannucci PM. The coagulopathy of chronic liver disease. The New England 
journal of medicine. 2011;365(2):147-56. 
REFERENCES 	  
	  124 
85. Lisman T, Leebeek FW, Mosnier LO, Bouma BN, Meijers JC, Janssen HL, et al. Thrombin-
activatable fibrinolysis inhibitor deficiency in cirrhosis is not associated with increased plasma 
fibrinolysis. Gastroenterology. 2001;121(1):131-9. 
86. Caldwell SH, Hoffman M, Lisman T, Macik BG, Northup PG, Reddy KR, et al. Coagulation 
disorders and hemostasis in liver disease: pathophysiology and critical assessment of current 
management. Hepatology. 2006;44(4):1039-46. 
87. Rijken DC, Kock EL, Guimaraes AH, Talens S, Darwish Murad S, Janssen HL, et al. Evidence 
for an enhanced fibrinolytic capacity in cirrhosis as measured with two different global fibrinolysis 
tests. Journal of thrombosis and haemostasis : JTH. 2012;10(10):2116-22. 
88. Colucci M, Binetti BM, Branca MG, Clerici C, Morelli A, Semeraro N, et al. Deficiency of 
thrombin activatable fibrinolysis inhibitor in cirrhosis is associated with increased plasma 
fibrinolysis. Hepatology. 2003;38(1):230-7. 
89. Abdel-Razik A, Mousa N, Elhelaly R, Tawfik A. De-novo portal vein thrombosis in liver 
cirrhosis: risk factors and correlation with the Model for End-stage Liver Disease scoring system. 
European journal of gastroenterology & hepatology. 2015;27(5):585-92. 
90. Chen H, Trilok G, Wang F, Qi X, Xiao J, Yang C. A single hospital study on portal vein 
thrombosis in cirrhotic patients - clinical characteristics & risk factors. The Indian journal of 
medical research. 2014;139(2):260-6. 
91. Ikura Y, Ohsawa M, Okada M, Iwai Y, Wakasa K. The significance of platelet consumption 
in the development of thrombocytopenia in patients with cirrhosis. The American journal of the 
medical sciences. 2013;346(3):199-203. 
92. Sogaard KK, Horvath-Puho E, Gronbaek H, Jepsen P, Vilstrup H, Sorensen HT. Risk of 
venous thromboembolism in patients with liver disease: a nationwide population-based case-
control study. The American journal of gastroenterology. 2009;104(1):96-101. 
93. Wu H, Nguyen GC. Liver cirrhosis is associated with venous thromboembolism among 
hospitalized patients in a nationwide US study. Clinical gastroenterology and hepatology : the 
official clinical practice journal of the American Gastroenterological Association. 2010;8(9):800-5. 
94. Ambrosino P, Tarantino L, Di Minno G, Paternoster M, Graziano V, Petitto M, et al. The risk 
of venous thromboembolism in patients with cirrhosis. A systematic review and meta-analysis. 
Thrombosis and haemostasis. 2017;117(1):139-48. 
95. Dabbagh O, Oza A, Prakash S, Sunna R, Saettele TM. Coagulopathy does not protect 
against venous thromboembolism in hospitalized patients with chronic liver disease. Chest. 
2010;137(5):1145-9. 
REFERENCES 
	   125 
96. Kalambokis GN, Oikonomou A, Christou L, Baltayiannis G. High von Willebrand factor 
antigen levels and procoagulant imbalance may be involved in both increasing severity of cirrhosis 
and portal vein thrombosis. Hepatology. 2016;64(4):1383-5. 
97. Tang W, Wang Y, Zhao X, Wang X, Zhang T, Ou X, et al. Procoagulant imbalance 
aggravated with falling liver function reserve, but not associated with the presence of portal vein 
thrombosis in cirrhosis. European journal of gastroenterology & hepatology. 2015;27(6):672-8. 
98. Chen H, Qi X, He C, Yin Z, Fan D, Han G. Coagulation imbalance may not contribute to the 
development of portal vein thrombosis in patients with cirrhosis. Thrombosis research. 
2013;131(2):173-7. 
99. Martinelli I, Primignani M, Aghemo A, Reati R, Bucciarelli P, Fabris F, et al. High levels of 
factor VIII and risk of extra-hepatic portal vein obstruction. Journal of hepatology. 2009;50(5):916-
22. 
100. Zhang D, Hao J, Yang N. Protein C and D-dimer are related to portal vein thrombosis in 
patients with liver cirrhosis. Journal of gastroenterology and hepatology. 2010;25(1):116-21. 
101. Zhang DL, Hao JY, Yang N. Value of D-dimer and protein S for diagnosis of portal vein 
thrombosis in patients with liver cirrhosis. The Journal of international medical research. 
2013;41(3):664-72. 
102. Singhal A, Karachristos A, Bromberg M, Daly E, Maloo M, Jain AK. Hypercoagulability in 
end-stage liver disease: prevalence and its correlation with severity of liver disease and portal vein 
thrombosis. Clinical and applied thrombosis/hemostasis : official journal of the International 
Academy of Clinical and Applied Thrombosis/Hemostasis. 2012;18(6):594-8. 
103. Mahmoud AE, Elias E, Beauchamp N, Wilde JT. Prevalence of the factor V Leiden mutation 
in hepatic and portal vein thrombosis. Gut. 1997;40(6):798-800. 
104. Janssen HL, Meinardi JR, Vleggaar FP, van Uum SH, Haagsma EB, van Der Meer FJ, et al. 
Factor V Leiden mutation, prothrombin gene mutation, and deficiencies in coagulation inhibitors 
associated with Budd-Chiari syndrome and portal vein thrombosis: results of a case-control study. 
Blood. 2000;96(7):2364-8. 
105. Amitrano L, Brancaccio V, Guardascione MA, Margaglione M, Iannaccone L, D'Andrea G, et 
al. Inherited coagulation disorders in cirrhotic patients with portal vein thrombosis. Hepatology. 
2000;31(2):345-8. 
106. Erkan O, Bozdayi AM, Disibeyaz S, Oguz D, Ozcan M, Bahar K, et al. Thrombophilic gene 
mutations in cirrhotic patients with portal vein thrombosis. European journal of gastroenterology 
& hepatology. 2005;17(3):339-43. 
REFERENCES 	  
	  126 
107. Amitrano L, Guardascione MA, Ames PR, Margaglione M, Iannaccone L, Brancaccio V, et al. 
Increased plasma prothrombin concentration in cirrhotic patients with portal vein thrombosis and 
prothrombin G20210A mutation. Thrombosis and haemostasis. 2006;95(2):221-3. 
108. Mangia A, Villani MR, Cappucci G, Santoro R, Ricciardi R, Facciorusso D, et al. Causes of 
portal venous thrombosis in cirrhotic patients: the role of genetic and acquired factors. European 
journal of gastroenterology & hepatology. 2005;17(7):745-51. 
109. Dentali F, Galli M, Gianni M, Ageno W. Inherited thrombophilic abnormalities and risk of 
portal vein thrombosis. a meta-analysis. Thrombosis and haemostasis. 2008;99(4):675-82. 
110. Qi X, Ren W, De Stefano V, Fan D. Associations of coagulation factor V Leiden and 
prothrombin G20210A mutations with Budd-Chiari syndrome and portal vein thrombosis: a 
systematic review and meta-analysis. Clinical gastroenterology and hepatology : the official 
clinical practice journal of the American Gastroenterological Association. 2014;12(11):1801-12 e7. 
111. Qi X, Yang Z, De Stefano V, Fan D. Methylenetetrahydrofolate reductase C677T gene 
mutation and hyperhomocysteinemia in Budd-Chiari syndrome and portal vein thrombosis: A 
systematic review and meta-analysis of observational studies. Hepatology research : the official 
journal of the Japan Society of Hepatology. 2014;44(14):E480-98. 
112. McLornan D, Percy M, McMullin MF. JAK2 V617F: a single mutation in the 
myeloproliferative group of disorders. The Ulster medical journal. 2006;75(2):112-9. 
113. Plessier A, Darwish-Murad S, Hernandez-Guerra M, Consigny Y, Fabris F, Trebicka J, et al. 
Acute portal vein thrombosis unrelated to cirrhosis: a prospective multicenter follow-up study. 
Hepatology. 2010;51(1):210-8. 
114. Kiladjian JJ, Cervantes F, Leebeek FW, Marzac C, Cassinat B, Chevret S, et al. The impact of 
JAK2 and MPL mutations on diagnosis and prognosis of splanchnic vein thrombosis: a report on 
241 cases. Blood. 2008;111(10):4922-9. 
115. Saugel B, Lee M, Feichtinger S, Hapfelmeier A, Schmid RM, Siveke JT. Thrombophilic factor 
analysis in cirrhotic patients with portal vein thrombosis. Journal of thrombosis and thrombolysis. 
2015;40(1):54-60. 
116. Li M, De Stefano V, Song T, Zhou X, Guo Z, Zhu J, et al. Prevalence of CALR mutations in 
splanchnic vein thrombosis: A systematic review and meta-analysis. Thrombosis research. 
2018;167:96-103. 
117. Turon F, Cervantes F, Colomer D, Baiges A, Hernandez-Gea V, Garcia-Pagan JC. Role of 
calreticulin mutations in the aetiological diagnosis of splanchnic vein thrombosis. Journal of 
hepatology. 2015;62(1):72-4. 
REFERENCES 
	   127 
118. Plompen EP, Valk PJ, Chu I, Darwish Murad SD, Plessier A, Turon F, et al. Somatic 
calreticulin mutations in patients with Budd-Chiari syndrome and portal vein thrombosis. 
Haematologica. 2015;100(6):e226-8. 
119. Violi F, Ferro D, Valesini G, Quintarelli C, Balsano F. Lupus anticoagulant in liver cirrhosis. 
Thrombosis and haemostasis. 1988;59(2):335. 
120. Violi F, Ferro D, Quintarelli C, Alessandri C, Saliola M, Valesini G, et al. Dilute aPTT 
prolongation by antiphospholipid antibodies in patients with liver cirrhosis. Thrombosis and 
haemostasis. 1990;63(2):183-6. 
121. Violi F, Ferro D, Basili S, D'Angelo A, Mazzola G, Quintarelli C, et al. Relation between 
lupus anticoagulant and splanchnic venous thrombosis in cirrhosis of the liver. Bmj. 
1994;309(6949):239-40. 
122. Romero Gomez M, Suarez Garcia E, Lopez Lacomba D, Marchante I, Grande L, Castro 
Fernandez M. Antiphospholipid antibodies are related to portal vein thrombosis in patients with 
liver cirrhosis. Journal of clinical gastroenterology. 2000;31(3):237-40. 
123. Perney P, Biron-Andreani C, Joomaye Z, Fabbro-Peray P, Quenet F, Schved JF, et al. 
Antiphospholipid antibodies in alcoholic liver disease are influenced by histological damage but 
not by alcohol consumption. Lupus. 2000;9(6):451-5. 
124. Ambrosino P, Lupoli R, Spadarella G, Tarantino P, Di Minno A, Tarantino L, et al. 
Autoimmune liver diseases and antiphospholipid antibodies positivity: a meta-analysis of 
literature studies. Journal of gastrointestinal and liver diseases : JGLD. 2015;24(1):25-34, 3 p 
following  
125. Uthman I, Khamashta M. The abdominal manifestations of the antiphospholipid 
syndrome. Rheumatology. 2007;46(11):1641-7. 
126. Amitrano L, Ames PR, Guardascione MA, Lopez LR, Menchise A, Brancaccio V, et al. 
Antiphospholipid antibodies and antiphospholipid syndrome: role in portal vein thrombosis in 
patients with and without liver cirrhosis. Clinical and applied thrombosis/hemostasis : official 
journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis. 
2011;17(4):367-70. 
127. Qi X, De Stefano V, Su C, Bai M, Guo X, Fan D. Associations of antiphospholipid antibodies 
with splanchnic vein thrombosis: a systematic review with meta-analysis. Medicine. 
2015;94(4):e496. 
128. McConnell M, Iwakiri Y. Biology of portal hypertension. Hepatology international. 
2018;12(Suppl 1):11-23. 
REFERENCES 	  
	  128 
129. Iwakiri Y, Shah V, Rockey DC. Vascular pathobiology in chronic liver disease and cirrhosis - 
current status and future directions. Journal of hepatology. 2014;61(4):912-24. 
130. Zironi G, Gaiani S, Fenyves D, Rigamonti A, Bolondi L, Barbara L. Value of measurement of 
mean portal flow velocity by Doppler flowmetry in the diagnosis of portal hypertension. Journal of 
hepatology. 1992;16(3):298-303. 
131. Lutz HH, Gassler N, Tischendorf FW, Trautwein C, Tischendorf JJ. Doppler ultrasound of 
hepatic blood flow for noninvasive evaluation of liver fibrosis compared with liver biopsy and 
transient elastography. Digestive diseases and sciences. 2012;57(8):2222-30. 
132. Zoli M, Iervese T, Merkel C, Bianchi G, Magalotti D, Marchesini G, et al. Prognostic 
significance of portal hemodynamics in patients with compensated cirrhosis. Journal of 
hepatology. 1993;17(1):56-61. 
133. Amitrano L, Guardascione MA, Ames PR. Coagulation abnormalities in cirrhotic patients 
with portal vein thrombosis. Clinical laboratory. 2007;53(9-12):583-9. 
134. Vaughan RB, Chin-Dusting JP. Current pharmacotherapy in the management of cirrhosis: 
focus on the hyperdynamic circulation. Expert opinion on pharmacotherapy. 2003;4(5):625-37. 
135. Brunner F, Berzigotti A, Bosch J. Prevention and treatment of variceal haemorrhage in 
2017. Liver international : official journal of the International Association for the Study of the 
Liver. 2017;37 Suppl 1:104-15. 
136. Qi XS, Bai M, Fan DM. Nonselective beta-blockers may induce development of portal vein 
thrombosis in cirrhosis. World journal of gastroenterology. 2014;20(32):11463-6. 
137. Pellicelli AM, D'Ambrosio C, Barbaro G, Villani R, Guarascio P, Fondacaro L, et al. Clinical 
And Genetic Factors Associated To Development Of Portal Vein Thrombosis In Cirrhotic Patients 
Without Hepatocellular Carcinoma. Journal of hepatology. 2011;54:S77. 
138. Philips CA, Arora A, Shetty R, Kasana V. A Comprehensive Review of Portosystemic 
Collaterals in Cirrhosis: Historical Aspects, Anatomy, and Classifications. International journal of 
hepatology. 2016;2016:6170243. 
139. James S. Dooley ASFL, Guadalupe Garcia-Tsao, Massimo Pinzani. Sherlock's Diseases of 
the Liver and Biliary System, 13th Edition. Wiley-Blackwell. 2018(13). 
140. Bagheri Lankarani K, Homayon K, Motevalli D, Heidari ST, Alavian SM, Malek-Hosseini SA. 
Risk Factors for Portal Vein Thrombosis in Patients With Cirrhosis Awaiting Liver Transplantation 
in Shiraz, Iran. Hepatitis monthly. 2015;15(12):e26407. 
141. Hernandez Conde M, Llop Herrera E, de la Revilla Negro J, Pons Renedo F, Fernandez Puga 
N, Martinez Porras JL, et al. Prevalence and outcome of portal thrombosis in a cohort of cirrhotic 
REFERENCES 
	   129 
patients undergoing liver transplantation. Revista espanola de enfermedades digestivas : organo 
oficial de la Sociedad Espanola de Patologia Digestiva. 2016;108(11):716-20. 
142. Li L, Duan M, Chen W, Jiang A, Li X, Yang J, et al. The spleen in liver cirrhosis: revisiting an 
old enemy with novel targets. Journal of translational medicine. 2017;15(1):111. 
143. Piscaglia F, Zironi G, Gaiani S, Mazziotti A, Cavallari A, Gramantieri L, et al. Systemic and 
splanchnic hemodynamic changes after liver transplantation for cirrhosis: a long-term 
prospective study. Hepatology. 1999;30(1):58-64. 
144. Westaby S, Wilkinson SP, Warren R, Williams R. Spleen size and portal hypertension in 
cirrhosis. Digestion. 1978;17(1):63-8. 
145. Witte CL, Witte MH, Renert W, Corrigan JJ, Jr. Splenic circulatory dynamics in congestive 
splenomegaly. Gastroenterology. 1974;67(3):498-505. 
146. Merkel C, Gatta A, Arnaboldi L, Zuin R. Splenic haemodynamics and portal hypertension in 
patients with liver cirrhosis and spleen enlargement. Clinical physiology. 1985;5(6):531-9. 
147. Bolognesi M, Merkel C, Sacerdoti D, Nava V, Gatta A. Role of spleen enlargement in 
cirrhosis with portal hypertension. Digestive and liver disease : official journal of the Italian 
Society of Gastroenterology and the Italian Association for the Study of the Liver. 2002;34(2):144-
50. 
148. Nagasue N, Dhar DK, Yamanoi A, Emi Y, Udagawa J, Yamamoto A, et al. Production and 
release of endothelin-1 from the gut and spleen in portal hypertension due to cirrhosis. 
Hepatology. 2000;31(5):1107-14. 
149. Wereszczynka-Siemiatkowska U, Swidnicka-Siergiejko A, Siemiatkowski A, Bondyra Z, 
Wasielica-Berger J, Mroczko B, et al. Endothelin 1 and transforming growth factor-beta1 correlate 
with liver function and portal pressure in cirrhotic patients. Cytokine. 2015;76(2):144-51. 
150. Garcia-Tsao G. Current Management of the Complications of Cirrhosis and Portal 
Hypertension: Variceal Hemorrhage, Ascites, and Spontaneous Bacterial Peritonitis. Digestive 
diseases. 2016;34(4):382-6. 
151. Ramanathan S, Khandelwal N, Kalra N, Bhatia A, Dhiman RK, Duseja AK, et al. Correlation 
of HVPG level with ctp score, MELD Score, ascites, size of varices, and etiology in cirrhotic 
patients. Saudi journal of gastroenterology : official journal of the Saudi Gastroenterology 
Association. 2016;22(2):109-15. 
152. Kayacetin E, Efe D, Dogan C. Portal and splenic hemodynamics in cirrhotic patients: 
relationship between esophageal variceal bleeding and the severity of hepatic failure. Journal of 
gastroenterology. 2004;39(7):661-7. 
REFERENCES 	  
	  130 
153. Rajendran P, Rengarajan T, Thangavel J, Nishigaki Y, Sakthisekaran D, Sethi G, et al. The 
vascular endothelium and human diseases. International journal of biological sciences. 
2013;9(10):1057-69. 
154. Feletou M.  The Endothelium: Part 1: Multiple Functions of the Endothelial Cells-Focus on 
Endothelium-Derived Vasoactive Mediators. Integrated Systems Physiology: from Molecule to 
Function to Disease. San Rafael (CA)2011. 
155. van Ierssel SH, Jorens PG, Van Craenenbroeck EM, Conraads VM. The endothelium, a 
protagonist in the pathophysiology of critical illness: focus on cellular markers. BioMed research 
international. 2014;2014:985813. 
156. Weinbaum S, Tarbell JM, Damiano ER. The structure and function of the endothelial 
glycocalyx layer. Annual review of biomedical engineering. 2007;9:121-67. 
157. Ince C, Mayeux PR, Nguyen T, Gomez H, Kellum JA, Ospina-Tascon GA, et al. The 
Endothelium in Sepsis. Shock. 2016;45(3):259-70. 
158. Esmon CT. The interactions between inflammation and coagulation. British journal of 
haematology. 2005;131(4):417-30. 
159. Schwameis M, Schorgenhofer C, Assinger A, Steiner MM, Jilma B. VWF excess and 
ADAMTS13 deficiency: a unifying pathomechanism linking inflammation to thrombosis in DIC, 
malaria, and TTP. Thrombosis and haemostasis. 2015;113(4):708-18. 
160. Grassle S, Huck V, Pappelbaum KI, Gorzelanny C, Aponte-Santamaria C, Baldauf C, et al. 
von Willebrand factor directly interacts with DNA from neutrophil extracellular traps. 
Arteriosclerosis, thrombosis, and vascular biology. 2014;34(7):1382-9. 
161. Turner N, Nolasco L, Nolasco J, Sartain S, Moake J. Thrombotic microangiopathies and the 
linkage between von Willebrand factor and the alternative complement pathway. Seminars in 
thrombosis and hemostasis. 2014;40(5):544-50. 
162. Rietveld IM, Lijfering WM, le Cessie S, Bos MHA, Rosendaal FR, Reitsma PH, et al. High 
levels of coagulation factors and venous thrombosis risk: strongest association for factor VIII and 
von Willebrand factor. Journal of thrombosis and haemostasis : JTH. 2018. 
163. von Kockritz L, De Gottardi A, Trebicka J, Praktiknjo M. Portal vein thrombosis in patients 
with cirrhosis. Gastroenterology report. 2017;5(2):148-56. 
164. Arab JP, Martin-Mateos RM, Shah VH. Gut-liver axis, cirrhosis and portal hypertension: the 
chicken and the egg. Hepatology international. 2018;12(Suppl 1):24-33. 
165. Fukui H. Gut-liver axis in liver cirrhosis: How to manage leaky gut and endotoxemia. World 
journal of hepatology. 2015;7(3):425-42. 
REFERENCES 
	   131 
166. Lin RS, Lee FY, Lee SD, Tsai YT, Lin HC, Lu RH, et al. Endotoxemia in patients with chronic 
liver diseases: relationship to severity of liver diseases, presence of esophageal varices, and 
hyperdynamic circulation. Journal of hepatology. 1995;22(2):165-72. 
167. Goodman ML, Way BA, Irwin JW. The inflammatory response to endotoxin. The Journal of 
pathology. 1979;128(1):7-14. 
168. Wang X. Lipopolysaccharide augments venous and arterial thrombosis in the mouse. 
Thrombosis research. 2008;123(2):355-60. 
169. Dalldorf FG, Jennette JC. Fatal meningococcal septicemia. Archives of pathology & 
laboratory medicine. 1977;101(1):6-9. 
170. Hook KM, Abrams CS. The loss of homeostasis in hemostasis: new approaches in treating 
and understanding acute disseminated intravascular coagulation in critically ill patients. Clinical 
and translational science. 2012;5(1):85-92. 
171. Patel KN, Soubra SH, Bellera RV, Dong JF, McMullen CA, Burns AR, et al. Differential role of 
von Willebrand factor and P-selectin on microvascular thrombosis in endotoxemia. 
Arteriosclerosis, thrombosis, and vascular biology. 2008;28(12):2225-30. 
172. Rumbaut RE, Bellera RV, Randhawa JK, Shrimpton CN, Dasgupta SK, Dong JF, et al. 
Endotoxin enhances microvascular thrombosis in mouse cremaster venules via a TLR4-dependent, 
neutrophil-independent mechanism. American journal of physiology Heart and circulatory 
physiology. 2006;290(4):H1671-9. 
173. Van de Wouwer M, Collen D, Conway EM. Thrombomodulin-protein C-EPCR system: 
integrated to regulate coagulation and inflammation. Arteriosclerosis, thrombosis, and vascular 
biology. 2004;24(8):1374-83. 
174. Ito T, Maruyama I. Thrombomodulin: protectorate God of the vasculature in thrombosis 
and inflammation. Journal of thrombosis and haemostasis : JTH. 2011;9 Suppl 1:168-73. 
175. Frederix K, Kooter IM, van Oerle R, Fens D, Hamulyak K, Gerlofs-Nijland ME, et al. A new 
method to determine tissue specific tissue factor thrombomodulin activities: endotoxin and 
particulate air pollution induced disbalance. Thrombosis journal. 2008;6:14. 
176. Starr ME, Ueda J, Takahashi H, Weiler H, Esmon CT, Evers BM, et al. Age-dependent 
vulnerability to endotoxemia is associated with reduction of anticoagulant factors activated 
protein C and thrombomodulin. Blood. 2010;115(23):4886-93. 
177. Faust SN, Levin M, Harrison OB, Goldin RD, Lockhart MS, Kondaveeti S, et al. Dysfunction 
of endothelial protein C activation in severe meningococcal sepsis. The New England journal of 
medicine. 2001;345(6):408-16. 
REFERENCES 	  
	  132 
178. Terada Y, Eguchi Y, Nosaka S, Toba T, Nakamura T, Shimizu Y. Capillary endothelial 
thrombomodulin expression and fibrin deposition in rats with continuous and bolus 
lipopolysaccharide administration. Laboratory investigation; a journal of technical methods and 
pathology. 2003;83(8):1165-73. 
179. Moore KL, Andreoli SP, Esmon NL, Esmon CT, Bang NU. Endotoxin enhances tissue factor 
and suppresses thrombomodulin expression of human vascular endothelium in vitro. The Journal 
of clinical investigation. 1987;79(1):124-30. 
180. Violi F, Lip GY, Cangemi R. Endotoxemia as a trigger of thrombosis in cirrhosis. 
Haematologica. 2016;101(4):e162-3. 
181. Lopez JA, Chen J. Pathophysiology of venous thrombosis. Thrombosis research. 2009;123 
Suppl 4:S30-4. 
182. Singh P, Yadav N, Visvalingam V, Indaram A, Bank S. Pylephlebitis--diagnosis and 
management. The American journal of gastroenterology. 2001;96(4):1312-3. 
183. Choudhry AJ, Baghdadi YM, Amr MA, Alzghari MJ, Jenkins DH, Zielinski MD. Pylephlebitis: a 
Review of 95 Cases. Journal of gastrointestinal surgery : official journal of the Society for Surgery 
of the Alimentary Tract. 2016;20(3):656-61. 
184. Chawla YK, Bodh V. Portal vein thrombosis. Journal of clinical and experimental 
hepatology. 2015;5(1):22-40. 
185. Stine JG, Shah NL, Argo CK, Pelletier SJ, Caldwell SH, Northup PG. Increased risk of portal 
vein thrombosis in patients with cirrhosis due to nonalcoholic steatohepatitis. Liver 
transplantation : official publication of the American Association for the Study of Liver Diseases 
and the International Liver Transplantation Society. 2015;21(8):1016-21. 
186. Nery F, Chevret S, Condat B, de Raucourt E, Boudaoud L, Rautou PE, et al. Causes and 
consequences of portal vein thrombosis in 1,243 patients with cirrhosis: results of a longitudinal 
study. Hepatology. 2015;61(2):660-7. 
187. Trinchet JC, Chaffaut C, Bourcier V, Degos F, Henrion J, Fontaine H, et al. Ultrasonographic 
surveillance of hepatocellular carcinoma in cirrhosis: a randomized trial comparing 3- and 6-
month periodicities. Hepatology. 2011;54(6):1987-97. 
188. Nery F, Correia S, Macedo C, Gandara J, Lopes V, Valadares D, et al. Nonselective beta-
blockers and the risk of portal vein thrombosis in patients with cirrhosis: results of a prospective 
longitudinal study. Alimentary pharmacology & therapeutics. 2019. 
189. Giannitrapani L, Grana W, Licata A, Schiavone C, Montalto G, Soresi M. Nontumorous 
Portal Vein Thrombosis in Liver Cirrhosis: Possible Role of beta-Blockers. Medical principles and 
practice : international journal of the Kuwait University, Health Science Centre. 2018. 
REFERENCES 
	   133 
190. Violi F, Corazza GR, Caldwell SH, Perticone F, Gatta A, Angelico M, et al. Portal vein 
thrombosis relevance on liver cirrhosis: Italian Venous Thrombotic Events Registry. Internal and 
emergency medicine. 2016;11(8):1059-66. 
191. Child CG, Turcotte JG. Surgery and portal hypertension. Major problems in clinical surgery. 
1964;1:1-85. 
192. Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R. Transection of the 
oesophagus for bleeding oesophageal varices. The British journal of surgery. 1973;60(8):646-9. 
193. Malinchoc M, Kamath PS, Gordon FD, Peine CJ, Rank J, ter Borg PC. A model to predict poor 
survival in patients undergoing transjugular intrahepatic portosystemic shunts. Hepatology. 
2000;31(4):864-71. 
194. Stankovic Z. Four-dimensional flow magnetic resonance imaging in cirrhosis. World 
journal of gastroenterology. 2016;22(1):89-102. 
195. Zampino R, Lebano R, Coppola N, Macera M, Grandone A, Rinaldi L, et al. The use of 
nonselective beta blockers is a risk factor for portal vein thrombosis in cirrhotic patients. Saudi 
journal of gastroenterology : official journal of the Saudi Gastroenterology Association. 
2018;24(1):25-9. 
196. Henriksen JH, Ring-Larsen H, Kanstrup IL, Christensen NJ. Splanchnic and renal elimination 
and release of catecholamines in cirrhosis. Evidence of enhanced sympathetic nervous activity in 
patients with decompensated cirrhosis. Gut. 1984;25(10):1034-43. 
197. Henriksen JH, Moller S, Ring-Larsen H, Christensen NJ. The sympathetic nervous system in 
liver disease. Journal of hepatology. 1998;29(2):328-41. 
198. Valla D, Gaudin C, Geoffroy P, Braillon A, Lee SS, Lebrec D. Reversal of adrenaline-induced 
increase in azygos blood flow in patients with cirrhosis receiving propranolol. Journal of 
hepatology. 1987;4(1):86-92. 
199. Mazoyer E, Ripoll L, Gueguen R, Tiret L, Collet JP, dit Sollier CB, et al. Prevalence of factor V 
Leiden and prothrombin G20210A mutation in a large French population selected for 
nonthrombotic history: geographical and age distribution. Blood coagulation & fibrinolysis : an 
international journal in haemostasis and thrombosis. 2009;20(7):503-10. 
200. Li J, Kim K, Barazia A, Tseng A, Cho J. Platelet-neutrophil interactions under 
thromboinflammatory conditions. Cellular and molecular life sciences : CMLS. 2015;72(14):2627-
43. 
201. Lalor PF, Herbert J, Bicknell R, Adams DH. Hepatic sinusoidal endothelium avidly binds 
platelets in an integrin-dependent manner, leading to platelet and endothelial activation and 
REFERENCES 	  
	  134 
leukocyte recruitment. American journal of physiology Gastrointestinal and liver physiology. 
2013;304(5):G469-78. 
202. Lee FY, Lu RH, Tsai YT, Lin HC, Hou MC, Li CP, et al. Plasma interleukin-6 levels in patients 
with cirrhosis. Relationship to endotoxemia, tumor necrosis factor-alpha, and hyperdynamic 
circulation. Scandinavian journal of gastroenterology. 1996;31(5):500-5. 
203. Kao JT, Yu CJ, Feng CL, Tsai SM, Chen YL, Wu YY. IL-6 significantly correlates with p-STAT3 
expression and presents high variceal bleeding with mortality in cirrhotic patients: A cross-
sectional study. Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi. 
2017;50(3):286-96. 
204. Eklund CM. Proinflammatory cytokines in CRP baseline regulation. Advances in clinical 
chemistry. 2009;48:111-36. 
205. Le Moine O, Deviere J, Devaster JM, Crusiaux A, Durand F, Bernuau J, et al. Interleukin-6: an 
early marker of bacterial infection in decompensated cirrhosis. Journal of hepatology. 
1994;20(6):819-24. 
206. Park WB, Lee KD, Lee CS, Jang HC, Kim HB, Lee HS, et al. Production of C-reactive protein 
in Escherichia coli-infected patients with liver dysfunction due to liver cirrhosis. Diagnostic 
microbiology and infectious disease. 2005;51(4):227-30. 
207. Loffredo L, Pastori D, Farcomeni A, Violi F. Effects of Anticoagulants in Patients With 
Cirrhosis and Portal Vein Thrombosis: A Systematic Review and Meta-analysis. Gastroenterology. 
2017;153(2):480-7 e1. 
208. Serste T, Melot C, Francoz C, Durand F, Rautou PE, Valla D, et al. Deleterious effects of 
beta-blockers on survival in patients with cirrhosis and refractory ascites. Hepatology. 
2010;52(3):1017-22. 
 
